Lists of funding opportunities are updated weekly. New funding opportunities for scientists are distributed in the VPRI Update newsletter.
To submit funding opportunities, and/or be added to the VPRI Update mailing list, please send your request to VPRI@unityhealth.to
Opportunities are categorized by Sponsor Type (Tri-Agency, Other Canadian, International & NIH). Filter opportunities by keyword (e.g. Sponsor Type, CIHR, user-supplied keyword, etc.) using the Search box at right.
| Sponsor Type | Funding Program Title | Amount and Duration | Description | Deadline | |
|---|---|---|---|---|---|
| Tri-Agency | CIHR Operating Grant: Data Analysis Using Existing CDN Databases and Cohorts | Up to $75,000 for up to 1 year. | This support projects that use data from existing Canadian-based cohorts, databases, cohort catalogues, and data platforms, and are relevant to human development, child and/or youth health, with the goal to inform improved patient, population, and system outcomes. Separate funding pools will support projects relevant to both the overall purpose and the following priority research areas: Indigenous research in human development, child and youth health; Infection and immunity research in human development, child and youth health. | Registration: September 10, 2024. Application: October 3, 2024. | |
| Tri-Agency | CIHR Catalyst Grant: Moving Upstream: Structural Determinants of Health | Up to $125,000 for 1 year. | This is to support robust research to analyze, monitor, contextualize and/or evaluate how structural or “system-level” drivers (e.g. legislation and policies) can create, maintain or exacerbate health (in) equity across populations, regions, contexts and settings. | Registration: September 11, 2024. Application: October 9, 2024. | |
| Tri-Agency | NSERC: Idea to Innovation (I2I) Grant | Market assessment ($15,000), Phase I ($125,000), Phase Ib ($60,000), Phase IIa ($125,000), Phase IIb ($350,000). | This opportunity aims to accelerate the pre-competitive development of promising technology originating from the university and college sector, and promote its transfer to a new or established Canadian company. | September 16, 2024. | |
| Tri-Agency | CIHR Team Grant: Biomedical Research for HIV/AIDS and STBBI | $400,000/year for up to 5 years (Team Grants); $750,000/year for up to 5 years (Large Team Grants). | This funding opportunity will support applications relevant to innovative technologies and next-generation interventions for STBBI across the cascade of care, from prevention to detection, to treatment and cure. This includes, but is not limited to, discovery research in biology, immunology, and pathology that contributes to the design, development, and implementation of interventions in the following two research areas: Next-Generation Therapeutic Interventions and Next-Generation Prevention Technologies. | September 17, 2024. | |
| Tri-Agency | CIHR: Institute of Nutrition, Metabolism and Diabetes (INMD) Training and Community Support Grant | $50,000 for 1 year. | This opportunity will support INMD research communities, including researchers and Partner Organizations (i.e., voluntary health sector organizations such as non-profit organizations, professional organizations and registered charities), to build pan-Canadian training programs in research domains largely and directly relevant to the Institute's mandate. | October 1, 2024. | |
| Tri-Agency | CIHR Chair: Implementation Science Chairs in HDCYH | Salary award: $100,000 per year as a salary contribution; Research allowance: $100,000 per year as a grant component. Term of up to 5 years. | This is to fund early-career and/or mid-career researchers using a Chair model to advance Implementation Science within the field of human development, child, and youth health with the ultimate goal of promoting health and health equity. At the time of application, the NPA must have at least 60% protected time for research. | October 15, 2024. | |
| Tri-Agency | CIHR Catalyst Grant: Biomedical Research for HIV/AIDS and STBBI | Up to $200,000 for 1 year. | This is to catalyze and strengthen the innovation landscape of HIV/AIDS and STBBI biomedical research in Canada in order to address the most pressing and persistent biomedical challenges to effective treatment of key populations disproportionately affected by STBBI. | October 23, 2024 | |
| Tri-Agency | CIHR Catalyst Grant: Analysis of Canadian Longitudinal Study in Aging (CLSA) Data (2024) | Up to $70,000 for up to 1 year. | The CLSA is a large, national, long-term study/platform that will follow approximately 50,000 men and women between the ages of 45 and 85 at study inclusion for at least 20 years. The specific objective of this funding opportunity is to catalyze and support research efforts of Canadian researchers to use the available CLSA data in order to better understand how biological, medical, psychological, social, lifestyle and/or economic aspects of people's lives have an impact on both maintaining health and the development of disease and disability as people age. | Registration: October 1, 2024. Application: October 30, 2024. | |
| Tri-Agency | CIHR Operating Grant: Healthy Cities Research Initiative (HCRI) - Data Analysis Using Existing Databases and Cohorts | Up to $100,000 for up to 1 year. | This HCRI funding opportunity will support research that leverages existing data to improve the health, wellness and health equity of urban populations. The goal of the Data Analysis Grants is to use existing cohorts, data platforms and/or administrative datasets to advance healthy cities intervention research and implementation science. | November 7, 2024. | |
| Tri-Agency | CIHR Operating Grant: HCRI - Data Analysis Using Existing Databases and Cohorts | Up to $100,000 for up to 1 year. | This supports research that leverages existing data to improve the health, wellness and health equity of urban populations. The goal is to use existing cohorts, data platforms and/or administrative datasets to advance healthy cities intervention research and implementation science. | November 7, 2024. | |
| Tri-Agency | SSHRC Partnership Development Grants | Between $75,000 and $200,000 for 1-3 years. | These grants are expected to are expected to respond to the objectives of the Research Partnerships program. They provide support to teams/partnerships, led by a project director, to: develop research and/or related activities in the social sciences and humanities; design and test new partnership approaches for research and/or related activities that can result in best practices or models. Applicants are expected to are expected to include a plan to seek and secure cash and/or in-kind contributions for their initiative during the life of the grant. | November 15, 2024. | |
| Tri-Agency | CIHR Other: Planning and Dissemination Grants – ICS | Up to $100,000 for 1 year. | These support planning activities, partnership development and to increase understanding of the health research landscape that will contribute to the advancement of research consistent with the mandate of CIHR; and support dissemination events and activities that focus on the communication of health research evidence to the appropriate researcher or knowledge-user audiences, tailoring the message and medium as appropriate. | November 19, 2024. | |
| Tri-Agency | CIHR Team Grant: Healthy Youth (2024) | Up to $300,000 per year for up to 5 years. | The purpose of this funding opportunity is to support research teams that bring evidence to at least two of the six youth-identified priorities of Canada’s Youth Policy to inform meaningful change that improves youth health and well-being. The six priority areas are: Leadership and Impact; Health and Wellness; Innovation, Skills and Learning; Employment; Truth and Reconciliation; Environment and Climate Action. | Registration: December 10, 2024; Application: February 4, 2025. | |
| Tri-Agency | CIHR Notice of Upcoming Funding Opportunity: Moving Upstream - Structural Determinants of Health Catalyst Grants | Up to $125,000 for one year. | This funding opportunity will support interdisciplinary research to analyze, contextualize and/or evaluate how structural drivers can create, maintain, or exacerbate health (in) equity and population health across sub-groups, regions, contexts and settings. The desired outcome is to contribute to the evidence base in Canada on the structural drivers that improve, sustain, or deteriorate population health and health equity. | Anticipated Deadlines: Registration: Fall 2024. Application: Fall 2024. | |
| Tri-Agency | CIHR Notice of Upcoming Funding Opportunity: Canadian Consortium on Neurodegeneration in Aging (CCNA) Phase III: Research Teams | Up to $250,000 per year for up to 4 years | This is open to the diverse neurodegenerative diseases research community to carry out research projects that align with Canada’s National Dementia Strategy (NDS) and the three Canadian Consortium on Neurodegeneration in Aging (CCNA) research themes (primary prevention, secondary prevention and treatment, quality of life). All applicant teams are required to leverage the CCNA Operations Centre's Central Resource Supports, however, they are not required to use CCNA data sets. | Registration: November 6, 2024 Application: December 11, 2024 | |
| Tri-Agency | CIHR Catalyst Grant: Digital Health | Up to $250,000 per year for up to 4 years | This funding opportunity will catalyze discovery in digital health, advance pivotal research, and inform applications or interventions relevant to CIHR- Institute of Musculoskeletal Health and Arthritis (IMHA)’s broad mandate areas. CIHR-IMHA will invest in digital health research that has the potential for immediate-to-medium term health impact (2-10 years). | December 3, 2024. | |
| Tri-Agency | NSERC Alliance Grants | $20,000 to $1 million per year for 1-5 years | Support university researchers to collaborate with partner organizations, which can be from the private, public or not-for-profit sectors. NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office. | No Deadline | |
| Tri-Agency | NSERC Alliance International | Catalyst Grants: $25,000 for 1 year. Collaboration Grants: Up to $100,000 per year for up to 3 years. | These are for Canadian university researchers working in the natural sciences and engineering in partnership with international collaborators from the academic sector ad t oestablish and grow international research collaborations and projects that have a high potential for impact in NSE disiplines. | No Deadline | |
| Tri-Agency | CIHR Notice of Upcoming Funding Opportunity: Community Based Research in Climate Change Priority Areas | Up to $125,000 for one year. | The purpose of this funding opportunity is to support the partnered work of communities and researchers in knowledge development and capacity-building initiatives of relevance to communities working to combat the differential health impacts of climate change. This will support activities relevant to one of the following research areas: Climate Justice; Alternative Diagnoses of Lyme Disease; Food Security in Northern Communities; and Health Impacts of Climate Change on Older Adults. | Anticipated Deadlines: Registration: Late summer 2024. Application: Fall 2024. | |
| Other Canadian | New Frontiers in Research Fund (NFRF) 2024 Exploration Competition | Up to $125,000 per year (including indirect costs) for up to 2 years | The goal of the Exploration stream is to inspire high-risk, high-reward and interdisciplinary research. Exploration grants support research that pushes boundaries into exciting new areas. Researchers are encouraged to undertake research that would defy current paradigms; brings disciplines together in unexpected ways and from bold, innovative perspectives; and has the potential to be disruptive or deliver game-changing impacts. If you plan to apply, please contact VPRI@unityhealth.to by June 7. | Notice of Intent (not adjudicated): August 27, 2024. Full application: November 5, 2024. | |
| Other Canadian | Heart & Stroke Foundation of Canada - New Investigator Award: | Up to $180,000 for up to 3 years. | This is a salary award to support new investigators who have demonstrated excellence in their doctoral and post- doctoral training and wish to establish their own independent research career. | September 5, 2024. | |
| Other Canadian | Heart & Stroke Foundation of Canada - Postdoctoral Fellowship Award: | Up to $60,000 for up to 2 years. | This provides salary support to Canada’s top researchers across the career continuum to ensure the training, retention and success of Canada’s cardiovascular and cerebrovascular researchers. | September 5, 2024. | |
| Other Canadian | Veterans Affairs Canada (VAC) Joint Federal Research Funding Program for Military Personnel and Veterans Needs Assessment to identify priority health research areas for women and diverse members in the Canadian Armed Forces (CAF) | $200,000.00 | Veterans Affairs Canada (VAC) Joint Federal Research Funding Program for Military Personnel and Veterans Needs Assessment to identify priority health research areas for women and diverse members in the Canadian Armed Forces (CAF) | September 6, 2024. | |
| Other Canadian | Heart & Stroke Foundation of Canada - Doctoral Personnel Awards for Women’s Heart and/or Brain Health: | Up to $45,000 for up to 3 years. | The award aims to increase the number of researchers and clinician-scientists in Canadian universities and research institutions devoted specifically to women’s heart and/or brain health. | September 10, 2024. | |
| Other Canadian | Heart & Stroke Foundation of Canada - Postdoctoral Fellowship Award for Women’s Heart and/or Brain Health: | Up to $60,000 for up to 2 years. | This award is to enable Postdoctoral Fellows to pursue their program of research and engage with mentors as part of their training in the area of women’s heart and/or brain health research. | September 10, 2024. | |
| Other Canadian | U of T Data Sciences Institute (DSI): Data Access Grant | Up to $10,000 for up to 8 months | This funding is to cover costs associated with accessing and working with large data sources that are necessary to carry out data-intensive research projects. The purpose of these grants is to improve data accessibility for DSI researchers and to foster research by mitigating the high cost of access to data sets. | September 13, 2024. | |
| Other Canadian | Lung Cancer Canada: Geoffrey Ogram Memorial Research Grant | $25,000.00 | This supports advancement in lung cancer research programs that are anywhere in the continuum from basic, high impact discovery to translational work of direct relevance to the clinic and beyond. The goal is to provide a mechanism for scientists to study innovations and accelerate the application of new knowledge relating to the early detection of lung cancer and the etiology of lung cancer in different demographics and populations. | September 30, 2024. | |
| Other Canadian | Cystic Fibrosis Foundation (CFF) - Clinical Fellowships: | $75,000 for 1 year. | This is intended for those physicians who have already obtained their residency training and who wish to pursue additional clinical training in CF care. | October 1, 2024. | |
| Other Canadian | Cystic Fibrosis Foundation (CFF) - Research Fellowship Awards: | varies. | The goal of fellowship awards is to build capacity in CF research in Canada. Individuals who hold M.D. or Ph.D. degrees are eligible to apply. | October 1, 2024. | |
| Other Canadian | Diabetes Canada: Research Collaboration Support Grant | $3,000 - $20,000 per research collaboration activity | This opportunity is to: 1) support investigator or network-initiated collaboration activities to bring researchers together, 2) support collaboration among researchers, and between researchers and the broader diabetes stakeholder community (including people with lived experience), and 3) foster sharing of research ideas and development of new knowledge and solutions. | (Quarterly): October 10, 2024 | |
| Other Canadian | Veterans Affairs Canada (VAC) Joint Federal Research Funding Program for Military Personnel and Veterans: Systematic Review Exploring the Possible Effects of Military Occupational Exposures on Reproductive Health | $80,000 | This seeks submissions from researchers to conduct a systematic review exploring the possible effects of military occupational exposures on reproductive health outcomes in CAF military women and diverse members. Researchers are encouraged to use a broad search strategy so that applicable research from different militaries and contexts is included. Sub-analysis or interpretation may be needed to demonstrate generalizability to the CAF. | October 10, 2024. | |
| Other Canadian | Veterans Affairs Canada (VAC) Joint Federal Research Funding Program for Military Personnel and Veterans: AI-enabled Transfusion Algorithm for Personalized Trauma Care | $140,000 for first year, $250,000 second year (dependent on funding funding availability) | This is to develop prototype predictive AI/ML models to assist trauma-induced blood transfusions. The models will use advanced machine learning algorithms and large-scale data to predict the need for massive hemorrhage protocol, the need for massive transfusion, and the transfusion of blood products (RBCs, plasma, and platelets) over time. The research can be conducted on a broader population, not just the Canadian Armed Forces (CAF) and Canadian Veteran populations. | October 10, 2024. | |
| Other Canadian | CQDM Connect-Pharma - Call for Ideas: Platforms for Therapeutic Target Discovery | -- | CQDM is interested in technologies that enable the discovery of novel targets in human disease including: Oncology, Neurology, Metabolic diseases, Rare diseases, Immunology. Exploratory techniques for target discovery can include, but are not limited to experimental, multiomic, and computational approaches. | October 10, 2024. | |
| Other Canadian | U of T Data Sciences Institute (DSI): Research Software Development Support Program | Software development support for 2-6 months on a part-time (up to a 0.5 FTE) basis. | This supports researchers to refine existing software tools to improve usability and robustness or to build new tools, disseminate research software beyond the research space in which it is created, and enhance existing functionality. It provides research groups access to a professional research software developer. Only open-source projects are considered for support. All PIs must be DSI members. | October 18, 2024. | |
| Other Canadian | Canadian Hemophilia Society (CHS): Dream of a Cure Research Program: | Up to $150,000 over 2 or 3 years | This supports research focused on improving the health and the quality of life of all people with inherited bleeding disorders and finding a cure. | November 29, 2024. | |
| Other Canadian | Canadian Hemophilia Society (CHS): CHS/Pfizer Care until Cure Research Program: | Up to $150,000 over 2 or 3 years | This supports research on medical and psychosocial aspects of bleeding disorders, including outcome evaluation. Grants are awarded for clinical research in fields relevant to improving the quality of life for persons with hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C, and carriers of an inherited bleeding disorder. | November 29, 2024. | |
| Other Canadian | Canadian Hemophilia Society (CHS): CHS – Bayer – ADVANCE Canada Research Program: | $45,000 for one year. | The research program will support studies that will identify and provide insight into key issues associated with the ageing hemophilia population; identify how management of age-related co-morbidities should be adapted to those with hemophilia; or generate and deliver evidence-based information to health care practitioners (HCPs), the public and policy makers that will lead to improved care and QoL for older Canadians living with hemophilia. | November 29, 2024. | |
| Other Canadian | Sigma/Canadian Nurses Foundation Grant | Up to USD $5,000. | This supports research that advances the practice of nursing with an emphasis on nursing care issues. Nursing care research or clinical nursing research is defined as research that is practice-based or that will provide the groundwork for future practice-based research studies. Research funded through this grant must provide evidence that there is a potential impact on nursing practice, whether direct or indirect. | December 1, 2024. | |
| Other Canadian | Multiple Sclerosis Society of Canada: Contract Research Organization (CRO) Grant | Up to $100,000 to pay for CRO services for up to a 1 year term. | This will enable principal investigators to apply for funding to pay for specific research services offered by CROs and specialized drug discovery and development organizations, with the aim of advancing research and development of treatments for progressive MS. | Open competition with no set deadline. | |
| Other Canadian | Grand Challenges Canada: Transition To Scale (TTS) Request for Proposals | Range from $250,000 to $3M for 6 months up to 2 years | This seeks to support the transition to scale and sustainability of Bold Ideas with Big Impact in Global Health. Applications are invited in the following areas: Maternal and Newborn Health, Digital Health, Medical Products and Technology, Community Health Worker Models, Urban Sanitation & Hygiene, and Options. | Concept notes accepted on a rolling basis | |
| Other Canadian | University of Toronto Institutional Strategic Initiatives (ISI) | From $50,000-$300,000 per year for up to 3 years. | ISI awards are intended to establish research capacity in high-priority areas, with the goal of realizing transformational impacts on issues of societal importance. | Ongoing | |
| Other Canadian | Collaboration Opportunities: National Research Council Canada (NRC) Challenge Programs | -- | The NRC offers potential opportunities for collaboration in the following areas: Aging in Place, Artificial Intelligence for Design, Disruptive Technology Solutions for Cell and Gene Therapy, High-throughput and Secure Networks, and Pandemic Response. | Ongoing | |
| Other Canadian | Rare Diseases: Models & Mechanisms Network Catalyst Grants | $25,000 | Catalyst Grants fund projects that will allow rapid confirmation of potentially disease-causing genes, and fuel pilot studies to improve understanding of how specific gene mutations cause disease. This application is intended for investigators who wish to link their gene discovery to a model organism researcher. | Continuous | |
| Other Canadian | Physicians' Services Incorporated (PSI) Foundation: Health Research Grant & New Investigator Grant | Health Research Grant: Up to $250,000 for 3 years. New Investigator Grant: Up to $300,000 for 3 years. | Areas of Support: clinical research, medical education research, health systems research. Applicant must be a College of Physicians and Surgeons of Ontario licensed MD. New Investigators must be within five years of their first academic appointment. | Rolling deadline | |
| Other Canadian | Alberta Gambling Research Institute (AGRI): Leveraging Grant | Up t0 $80,000 | To enable researchers, with non-AGRI funding to augment projects with a gambling-related component. | Rolling call | |
| Other Canadian | Alberta Gambling Research Institute (AGRI): Team Development Grants | Up to $10,000 for up to 18 months | To support the development of multi/interdisciplinary teams of academic researchers, among Partner Universities, nationally, internationally, and other stakeholders in order to establish research programs. | Rolling call | |
| Other Canadian | Alberta Gambling Research Institute (AGRI): Small Grants | Up to $10,000 for up to 1 year | To support small developmental initiatives typically intended to lead to major grant applications. | October 1st and May 1st each year | |
| Other Canadian | Telus Funds | Various | For entertaining and engaging web series with the potential to positively impact families and friends providing care for loved ones struggling with a health condition. | Various | |
| Other Canadian | Ontario Centre of Innovation (OCI) Voucher for Innovation and Productivity (VIP) Program | Minimum of $20,000 up to a maximum of $150,000 per year towards the direct costs of research (Industry Partner contribution has to be minimum of 1:1 cash match to the OCE contribution, where at least 50% must be spent at the post-secondary institution.) | This program helps companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario's industry and publicly funded post-secondary institutions and research hospitals. If you are interested, please contact Samar Saneinejad at Samar.Saneinejad@unityhealth.to | No Deadline | |
| Other Canadian | Multiple Sclerosis Society of Canada: Contract Research Organization (CRO) Grant | Up to $100,000 for 1 year | The CRO Grant will enable principal investigators to apply for funding to pay for specific research services offered by CROs and specialized drug discovery and development organizations, with the aim of advancing research and development of treatments for progressive MS. The CRO does not have to be based in Canada. | This is an open competition with no set deadline | |
| International | Alzheimer's Association: Research Grant: | Up to USD $200,000 for up to 3 years | This is to provide newly independent investigators with funding that will allow them to develop preliminary or pilot data, to test procedures and to develop hypotheses. Applicants must be an Assistant Professor or Associate Professor at their respective academic institution and less than 15 years past their doctoral degree or post-residency (M.D. or D.O.). | LOI: September 5, 2024; Full Application: November 12, 2024 | |
| International | Alzheimer's Association: Research Fellowship: | Up to USD $200,000 for up to 3 years | This is to support exceptional researchers who are engaged in their post-graduate work (i.e., postdoctoral fellows) and before they have their first independent faculty positions (i.e., Assistant Professor) and working in diverse areas of research, including basic, translational, clinical, functional and social-behavioral research. Investigators doing clinically-focused research without clinical practice are encouraged to apply to this program. | LOI: September 5, 2024; Full Application: November 12, 2024 | |
| International | Alzheimer's Association: Clinician Scientist Fellowship Program: | Up to USD $250,000 for up to 3 years | This is to support the training of clinician scientists, who is an individual already trained, licensed and practicing in a clinical field that includes patient contact or patient-related diagnostic studies, in Alzheimer's and all other dementias. Applicants must be clinicians interested in an academic career who have less than 15 years of research experience after receipt of their terminal degree. | LOI: September 5, 2024; Full Application: November 12, 2024 | |
| International | Alzheimer's Association: Research Grant - New to the Field: | Up to USD $200,000 for up to 3 years | This is to fund investigators who are new to Alzheimer's and all other dementia field of research. Applicants must be Assistant Professors or above at their respective academic institution and new to the field of neuroscience or neurodegeneration (Alzheimer’s, Parkinson’s, Lewy body dementia, Frontotemporal dementia, or Vascular dementia). | LOI: September 5, 2024; Full Application: November 12, 2024 | |
| International | Leukemia & Lymphoma Society (LLS): Research Accelerator for Follicular Lymphoma I (RAFL-I) | Synergistic Team Awards (STA) Value: USD $1.3M per year for up to 5 years. Translational Awards (TRL) Value: USD $350,000 per year for up to 5 years. | Research under the RAFL program will be aimed to understand the fundamental biology of FL progression, to develop new targets and therapies, and to launch clinical programs that can address the unmet FL patient needs. Ultimately, the overarching goal is to achieve a cure in which FL is eradicated, and therapy can be discontinued. Synergistic Team Awards (STA) will support a coordinated, focused and significant effort to understand central disease mechanisms and develop effective novel therapies in treating FL. Translational Awards (TRL) will support translational research that moves potential therapeutic candidates toward clinical trials within 2-3 years. | Letter of Intent: September 9, 2024; Full Application (by invitation): January 13, 2025. | |
| International | United States Department of Defense (DoD): Alcohol and Substance Abuse Disorders Consortium Award | Up to USD $4M for up to 5 years. | This supports the establishment of a Consortium whose purpose is to identify, evaluate, and advance pharmacotherapies for alcohol, opioid, and other substance use disorders, with an emphasis on other co-occurring mental health conditions, through rigorous, collaborative research efforts that translate basic knowledge and early-stage clinical products into evidence-based treatments. | Pre-application: September 10, 2024. Application: September 24, 2024. | |
| International | American Academy of Neurology (AAN): Richard Olney Clinician Scientist Development Award in ALS: | USD $75,000/year for 3 years, plus a $5,000/year stipend to support education and research-related costs | This award recognizes the importance of good clinical research and encourages early career investigators in clinical studies in ALS. Recipient must be an AAN member interested in an academic career in neurologic research with a MD, PhD equivalent doctoral-level clinical degree who has completed residency or a PhD no more than 7 years prior to the beginning of this award (July 1, 2025). | September 10, 2024. | |
| International | American Academy of Neurology (AAN): Neuroscience Research Training Scholarship: | USD $65,000/year for 2 years, plus a $10,000/year stipend | The award aims to recognize the importance of and encourage young investigators in, good laboratory or preclinical research. Recipient must be interested in an academic career in neurologic research with a MD, PhD or equivalent doctoral-level clinical degree who has completed clinical residency or PhD no more than 5 years to the beginning of this award (July 1). | September 10, 2024. | |
| International | American Academy of Neurology (AAN): Career Development Award: | USD $150,000/year for 3 years | This is to support junior investigators interested in an academic career in clinical, basic, or translational neurological research. Recipient must be a neurologist and an AAN member interested in an academic career in neurologic research who completed residency between 5-10 years prior to the beginning of this award (July 1, 2025). | September 10, 2024. | |
| International | American Academy of Neurology (AAN): Practice Research Training Scholarship: | USD $65,000/year for 2 years, plus a $10,000/year stipend | This is to support practice-based research, which is defined as “clinical research that evaluates translation of evidence into best clinical practice.” This may include evaluation of health services, quality of care, implementation of therapies, physician performance, or patient adherence. It is intended to create unique training opportunities previously difficult to access for neurologists. This award aims to recognize the importance of good practice-based research or comparative effectiveness research (CER) and encourage young investigators to use studies to improve health systems and services. | September 10, 2024. | |
| International | American Academy of Neurology (AAN): Clinical Research Training Scholarships: | USD $65,000/year for 2 years, plus a $10,000/year stipend | 13 Scholarships are available through different streams to recognize the importance of good clinical research and to encourage early career investigators in clinical studies. Please check link for more details. | September 10, 2024. | |
| International | Leducq Foundation International Networks of Excellence (INE) Program | USD $8,000,000 over 5 years. | The principal aim of this program is to foster outstanding and innovative scientific research by bringing together international teams of researchers with complementary expertise and resources to work together on a common thematic problem. The proposals should aim to generate new knowledge with the potential to advance the diagnosis, prevention, and treatment of cardiovascular and/or neurovascular disease. | Letter of Intent: September 11, 2024. Full Application (by invitation): February 14, 2025. | |
| International | International Association for the Study of Pain (IASP): Collaborative Research Grant | Up to USD $15,000 | This grant is to support international interdisciplinary pain research collaborations between at least two countries with an emphasis on collaborations among basic, translational, and clinical scientists. The principal investigator in charge of the overall project must have been a member of IASP for the past year from the date of application. | September 12, 2024 | |
| International | Brain & Behavior Research Foundation (BBRF): Distinguished Investigator Grant Program | Up to USD $100,000 for 1 year | This is to develop improved treatments, cures, and methods of prevention for mental illness. This grant program is intended for established scientists, full professor (or equivalent), who maintain peer reviewed competitively funded scientific programs. | September 12, 2024 | |
| International | US Department of Defense (DOD): Neurofibromatosis Research program Synergistic Idea Award | Up to USD $2M for 3 years | This is to support new ideas that represent synergistic approaches to NF research involving two or three Principal Investigators (PIs). Each PI must be at or above the level of Assistant Professor (or equivalent). These investigators should utilize their complementary and synergistic perspectives to address a central problem or question in NF research. | Pre-application: September 12, 2024; Full Application: October 3, 2024 | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Breast Cancer Research Program (BCRP) II Breakthrough Award Levels 1 and 2 II: | Funding Level 1: Up to USD $450,000 or up to USD $750,000 with the Partnering PI Option for up to 3 years; Funding Level 2: Up to USD $1.0M for up to 3 years. | Supports promising research that has high potential to lead to or make breakthroughs in breast cancer. | Pre-Application: September 12, 2024; Application: September 26, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Breast Cancer Research Program (BCRP) II Breakthrough Award Levels 1 and 2 II Clinical Research Extension Award II: | Up to USD $5.0M or up to USD $6.0M with the Partnering PI Option for up to 4 years | Supports research that extends or expands the data collection, follow-up, and analysis of breast cancer clinical studies. | Pre-Application: September 12, 2024; Application: September 26, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Breast Cancer Research Program (BCRP) II Transformative Breast Cancer Consortium Development Award II: | Up to USD $100,000 for up to 1 year. | Provides the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research. | Pre-Application: September 12, 2024; Application: September 26, 2024. | |
| International | Thoracic Surgery Foundation - STS Research Award: | Up to USD $90,000/year for up to 2 years | Veterans Affairs Canada (VAC) Joint Federal Research Funding Program for Military Personnel and Veterans Needs Assessment to identify priority health research areas for women and diverse members in the Canadian Armed Forces (CAF) | September 15, 2024. | |
| International | Thoracic Surgery Foundation - AstraZeneca Lung Cancer Research Award: | Up to USD $50,000/year for up to 2 years | This grant is for cardiothoracic surgeons, pulmonologists, or research or physician-scientists who are seeking initial support and recognition for their original research project related to lung cancer. Proposed projects should aim to reduce the burden of lung disease through the advancement of clinical, transitional and/or basic scientific research. | September 15, 2024. | |
| International | Breakthrough type 1 diabetes (T1D) - Mechanisms of Graft Acceptance in Clinical Islet Transplantation: | up to USD $750,000 for 2 years. | The goal of this funding opportunity is to expand the understanding of mechanisms contributing to long term survival/function and immune tolerance toward islet grafts following transplantation in T1D using existing clinical datasets. | LOI: September 17, 2024 Full Application: October 22, 2024. | |
| International | Breakthrough type 1 diabetes (T1D) - Development of devices and drugs for fully automated insulin delivery (AID) at meals: | USD $1M-2M for 2-3 years. | This is intended to support the development of AID systems, or components of an AID system. | LOI: September 17, 2024 Full Application: November 18, 2024. | |
| International | American Psychological Foundation (APF): Bruce and Jane Walsh Grant in memory of John Holland | USD $19,000. | Supports scientific, scholarly, or applied research and/or educational activities investigating how personality, culture, and environment influence work behavior and health (mental and physical). Applicants must be a graduate student or early career researcher (no more than 10 years postdoctoral). | September 18, 2024. | |
| International | Leukemia & Lymphoma Society (LLS): Discovery Grant Program (DGP) | Up to USD $250,000/year for up to 3 years. | This is to encourage basic research, technological innovation, and informatics pipeline development that can lead to an understanding of blood cancer disease mechanisms, the development of improved methods for detecting and monitoring cancer progression, and the identification of novel therapeutic targets. This is a dedicated mechanism to encourage established investigators to explore the biology of blood cancer and support proof-of-concept studies that could initiate completely novel approaches to treatment. | LOI: September 18, 2024; Full Application: March 25, 2025. | |
| International | Cabinet Office of Japan: Hideyo Noguchi Africa prize (Multiple Opportunities) | JPY 100 million (equivalent to about 1 million USD) | This prize aims to honour individuals with outstanding achievements in the fields of medical research and medical services to combat infectious and other diseases in Africa, thus contributing to the health and welfare of the African people and of all humankind. Nominations are accepted for achievements in: Medical Research and Medical Services | September 20, 2024. | |
| International | Pfizer Global Medical Grants & Partnerships (GMGP): Diagnosis and Risk Factors for Invasive Mold Infection (IFI) | Up to USD $75,000 | This is to support independent educational activities for health care professionals involved in the diagnosis and management of patients with invasive mold and yeast infections to improve the Management of patients with IFI. | September 22, 2024 | |
| International | Breakthrough type 1 diabetes (T1D) - Artificial Intelligence Powered Approaches for T1D Cell Therapy | Up to USD $750,000 over 3 years. | This is to expand the understanding of mechanisms contributing to long term survival/function and immune tolerance toward islet grafts following transplantation in type 1 diabetes (T1D) using existing clinical datasets and by leveraging advancements in artificial intelligence and machine learning. Proposals coming from multi-disciplinary teams comprised of both data scientists and expert T1D researchers will be prioritized. | LOI: September 23, 2024; Full Application: November 5, 2024. | |
| International | United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP): FY24 Kidney Cancer Research Program (KCRP)- Translational Research Partnership Award: | Up to USD $800,000 direct costs per project for up to 3 years. | Supports the development of translational research collaborations between two independent, faculty-level (or equivalent) investigators to address a central problem or question in kidney cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a research scientist and the other must be a clinician. | Pre-Application: September 24, 2024; Application: October 15, 2024. | |
| International | United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP): FY24 Kidney Cancer Research Program (KCRP) - Clinical Trial Award: | Up to USD $2.0M direct costs for up to 4 years. | Supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of kidney cancer. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. | Pre-Application: September 24, 2024; Application: October 15, 2024. | |
| International | United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP): FY24 Kidney Cancer Research Program (KCRP) -Idea Development Award: | Up to USD $2.0M direct costs for up to 4 years. | Supports innovative ideas and high-impact approaches, based on scientifically sound evidence, to move toward the KCRP vision of eliminating kidney cancer. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach. | Pre-Application: September 24, 2024; Application: October 15, 2024. | |
| International | United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP): FY24 Kidney Cancer Research Program (KCRP) - Kidney Cancer Academy of Kidney Cancer Investigators (AKCI) - Early-Career Scholar (ECS) Award: | Up to USD $725,000 direct costs for up to 4 years. | This is a virtual research capacity building and research mentoring platform that consists of ECS/Designated Mentor pairs from different institutions and an Academy Leadership Team. The ECS is expected to conduct research, participate in monthly webinars, and annual workshops, and communicate and collaborate with other members of the Academy (other ECS, mentors, Academy Leadership Team) as well as with the kidney cancer advocacy community. The ECS must be less than 5 years from their last postdoctoral research position (Ph.D.), clinical fellowship (M.D.), or equivalent as of the full application submission deadline. | Pre-Application: September 24, 2024; Application: October 15, 2024. | |
| International | New Horizon Europe funding calls | -- | The European Commission announced the launch of new funding calls in Cluster 1 Heath. The new calls for proposals are: European Partnership: One Health Anti-Microbial Resistance. (Deadline: September 25, 2024.); European partnership for pandemic preparedness; Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases – GACD); and Pre-commercial procurement for environmentally sustainable, climate neutral and circular health and care systems. | September 25, 2024; November 26, 2024. | |
| International | International Center for Responsible Gaming (ICRG) Request for Applications (RFA) for Research on Responsible Gambling and Prevention: | Up to USD $187,500 total for 2 years | The purpose of this funding opportunity is to advance the development, implementation and validation of interventions to minimize gambling-related harm. | September 30, 2024. | |
| International | Alzheimer's Drug Discovery Foundation: The Treat FTD (Frontotemporal Degeneration) Fund | USD $2.5M for 1-3 years. | This fund aims to support the development of drugs or devices for FTD disorders while building a better understanding of FTD pathophysiology, biological mechanisms of disease, and analytically and clinically validated biomarkers with a well-defined context-of-use. The fund aims to de-risk clinical development programs by supporting clinical trial readiness activities or early/mid-stage clinical trials with clear go/no-criteria for later stage drug development. Both disease-modifying and symptomatic approaches will be considered. | Letter of intent: September 30, 2024. Full application: December 9, 2024. | |
| International | Pfizer Global Medical Grants & Partnerships (GMGP) and International Bowel Ultrasound Group (IBUS): Request for Proposals (RFP) Closing the Gaps within Intestinal Ultrasound | Up to $100,000 total costs for 12 months. | This is for research initiatives focused on intestinal ultrasound (IUS) in inflammatory bowel disease (IBD) in the following priority areas: IUS in Monitoring IBD, Perianal IUS in Proctitis, IUS in Special Populations, IUS Education, IUS in monitoring treatment with Etrasimod in a real-world setting. Applicant must be an IBUS Member and may collaborate with another Organization or Institution. | October 1, 2024. | |
| International | American Psychological Foundation (APF): Scott and Paul Pearsall Grant | USD $10,000. | Supports graduate and early career work that seeks to increase the public’s understanding of the psychological pain and stigma experienced by adults living with visible physical disabilities, such as cerebral palsy. | October 2, 2024. | |
| International | American Psychological Foundation (APF): Dr. Diana Slaughter Kotzin and Mr. Joseph G. Kotzin Fund Grant | USD $9,500. | Supports research, practice, or education of an early career psychologist on the topic of child and youth suicide among African Americans. | October 2, 2024. | |
| International | Foundation Fighting Blindness (FFB): Free Family Age-Related Macular Degeneration (AMD) Award | USD $200,000/year for up to 3 years | This award for a meritorious research proposal that proposes to understand pathophysiologic mechanisms that cause the transition from aging to early, dry AMD. If successful, the research will inform the design of targeted treatment for the greatest number of people afflicted with early AMD and prevent blindness from late AMD. | LOI: October 03, 2024; Full Application: January 09, 2024 | |
| International | Combating Antibiotic Resistant Bacteria (CARB-X) | -- | CARB-X is accepting expressions of interest (EOI) for any of their four funding themes: (1) Therapeutics for infections caused by Gram-negative pathogens (2) Prevention of invasive diseases (3) Diagnostics for neonatal sepsis and (4) Proof-of-concept for alternative sample types for diagnosing lower-respiratory-tract infections. In the EOI, you will be asked to answer a series of questions about your proposed project and will be given the opportunity to share pertinent, non-confidential details. | October 4, 2024. | |
| International | Pfizer Global Medical Grants & Partnerships (GMGP): Early Diagnosis Improvement of Chlamydia Infections | Up to USD $100,000 for 1 year | This program seeks to support health care professionals medical education to improve early diagnosis of chlamydia infections. Potential applicants are encouraged to develop educational programs to identify and address the educational needs, barriers, and gaps for early diagnosis of chlamydia. | October 07, 2024 | |
| International | Breakthrough type 1 diabetes (T1D) - Accelerating clinical trials evaluating disease-modifying therapies for T1D: | up to USD $1.5M for 4 years. | This invites applications that propose clinical trials to test small molecules, biologics, and combination therapies to delay, halt, or reverse the progression of T1D. | LOI: October 10, 2024; Full Application: January 13, 2025. | |
| International | International Center for Responsible Gaming (ICRG) Request for Applications (RFA) on Research on the Language and Messaging of Prevention and Responsible Gambling Programs: | Up to USD $437,500 total for 3 years | This is to study the impact of safer gambling messaging including its impact on gambling behavior and use of responsible gambling tools. | October 15, 2024. | |
| International | US Department of Defense (DOD) Pre-announcements - The Arthritis Research Program (ATRP) Focused Research Award: | -- | This supports conceptually innovative, high-risk/potentially high-reward research that could ultimately lead to critical discoveries and/or improvements in patient care or quality of life for people impacted by arthritis. Clinical research and clinical trials are not allowed. There is Research Level 1 and Research Level 2 | Letter of Intent: October 16, 2024 Full application: October 30, 2024 | |
| International | US Department of Defense (DOD) Pre-announcements - The Arthritis Research Program (ATRP) - Clinical Research Award: | Base Level: Up to USD $1.5M for up to 4 years; Clinical Trial Option: Up to USD $3M for up to 4 years | Supports clinical research that evaluates disease-specific factors and interventions. Pre-clinical and animal research are not allowed. A Clinical Trial Option is available for applications proposing clinical trials. | Letter of Intent: October 16, 2024 Full application: October 30, 2024 | |
| International | Leukemia & Lymphoma Society (LLS): Translational Research Program | Up to USD $250,000/year for 3 years. | This funding opportunity is seeking applications that propose novel approaches to the prevention, diagnosis, or treatment of hematological malignancies and related pre-malignant conditions. Proposals should be based on molecular, cellular, or integrated systems findings and be conceptually innovative and with a clear plan for the eventual clinical translation of the studies proposed and the results expected. | Letter of intent: October 16, 2024. Application: January 21, 2025. | |
| International | Leukemia & Lymphoma Society (LLS) - Fellow Award: | Up to USD $220,800 for 3 years. | This is for a postdoctoral fellow whose research must be directly relevant to hematologic malignancies and/or relevant pre-malignant conditions. | October 18, 2024 (eligibility phase); November 1, 2024 (letter of intent); November 15, 2024 (full application). | |
| International | Leukemia & Lymphoma Society (LLS) - Scholar Award: | USD $600,000 for 5 years. | This supports rising stars in the blood cancer research field who has shown a capacity for independent, sustained, and original investigation in the field of hematologic malignancies and/or relevant pre-malignant conditions. | October 18, 2024 (eligibility phase); November 1, 2024 (letter of intent); November 15, 2024 (full application). | |
| International | Leukemia & Lymphoma Society (LLS) - Special Fellow: | USD $225,000 for 2-3 years. | This supports postdocs and instructors who have clearly demonstrated success in their current postdoctoral/instructor position, and who need an additional 2-3 years of training to be competitive for an independent position. | October 18, 2024 (eligibility phase); November 1, 2024 (letter of intent); November 15, 2024 (full application). | |
| International | Leukemia & Lymphoma Society (LLS) - Scholar in Clinical Research: | USD $625,000 for 5 years. | This supports rising stars in the clinical blood cancer research field who holds an independent faculty-level appointment and is conducting independent clinical research, often involving early-stage clinical trials, that will advance the prevention, diagnosis, or treatment of hematologic malignancies and/or relevant pre-malignant conditions. | October 18, 2024 (eligibility phase); November 1, 2024 (letter of intent); November 15, 2024 (full application). | |
| International | American Sleep Medicine Foundation (ASMF): Strategic Research Award | Category I: Up to $250,000 for 1-3 years; Category II: Up to $100,000 for 1-2 years; Category III: Up to $50,000 for up to 1 year | This grant is investigator-initiated and supports high-impact research projects aimed at addressing gaps in knowledge that impact the ability to provide optimal, patient-centered, cost-effective diagnosis and care for people with sleep disorders. Sleep scientists with a master’s level degree (MA, MS, MSN, MPH, or equivalent) or higher (MD, DO, DDS, DMD, DNP, DNSc, PharmD, PhD, or equivalent) are eligible to apply. | LOI: October 21, 2024; Full Application: March 10, 2025 | |
| International | American Psychological Foundation (APF): John and Polly Sparks Grant for Rural First-Responders Mental Health Interventions | Up to USD $34,000. | This will fund the research of psychologists for evidence-based research and intervention in providing mental health training dissemination to first responders in rural areas. | October 23, 2024. | |
| International | American Psychological Foundation (APF): John and Polly Sparks Grant for Rural First-Responders Mental Health Interventions | $34,000 | The APF John and Polly Sparks First-Responder Grant will fund research to examine evidence-based interventions to protect the mental health of first responders in rural areas, conducted by psychologists. | October 23, 2024. | |
| International | Breakthrough T1D: Diabetes Psychology Fellowship Program: | Up to USD $65,000/year for up to 2 years. | This program encourages type 1 diabetes (T1D) psychology research work or a combination of clinical psychological diabetes work and T1D psychology research. The applicant is required to work with a mentor who can provide a training environment conducive to a career in T1D-relevant psychosocial research. | October 23, 2024. | |
| International | Breakthrough T1D: Innovative Awards: | Up to USD $200,000. | This provides seed funding for highly innovative, high-risk-high-reward research with significant potential to accelerate the mission of Breakthrough T1D. Proposals should address key outstanding questions and have the potential to lead to a challenge or a change in the current paradigm or conventional wisdom and/or lead to a groundbreaking discovery. | October 24, 2024. | |
| International | Breakthrough T1D: Clinical Trials Advancing Metabolic Therapies for T1D: | Up to USD $2M for 3 years. | The goal of this funding opportunity is to target metabolic imbalances to improve glucometabolic outcomes in people with established T1D. Clinical trials evaluating therapies either approved or in development for metabolic diseases such as T2D, obesity, and MAFLD will be prioritized. | Letter of intent: October 31, 2024; Full proposal: January 7, 2025. | |
| International | Mendez National Institute of Transplantation Foundation (MNITF): Research Grant Program | Up to USD $150,000 for 2 years. | This grant program continues the vision and legacy of our founders by awarding grants semiannually to researchers to improve clinical outcomes and positively impact the field of transplantation. MNITF prioritize projects that could make a significant, immediate impact on advancing transplantation and for which funding is not available from other sources | Letter of intent: November 1, 2024. Full application: July 31, 2024; December 15, 2024. | |
| International | Breakthrough Type 1 diabetes (T1D): Project Concepts | -- | This is for Strategice Research Agreement Letters of Intent that address Breakthrough T1D’s current Research Strategy. | Round 1: LOI: November 6, 2024; Round 2: LOI: May 6, 2025. | |
| International | Society of American Gastrointestinal Endoscopic Surgeons (SAGES) - Disparities in Healthcare Grant: | Up to USD $20,000. | This call for research would prioritize grants or quality improvement projects to potentially reduce disparities in access to MIS and robotic surgery that could be adopted more widely to address this healthcare need. | November 15, 2024. | |
| International | Society of American Gastrointestinal Endoscopic Surgeons (SAGES) - Intuitive Surgical Robotic Surgery Grants: | Up to USD $50,000 for up to 2 years. | This is to stimulate original research in robotic surgery, focusing on the use of robotic surgery for procedures other than colorectal surgical procedures. Grants fostering collaborative research and focused on hernia repair will be prioritized in this competition. The committee will only consider grants that involve commercially available products. | November 15, 2024. | |
| International | Society of American Gastrointestinal Endoscopic Surgeons (SAGES) - Research Grant: | Up to USD $30,000 for 1 year. | This is to stimulate original research in gastrointestinal and endoscopic surgery. The study may be either “bench” research or clinical. | November 15, 2024. | |
| International | International Center for Responsible Gaming (ICRG): (RFA) for Research on Gambling Industry Employees | Up to USD $187,500 total for up to 2 years. | Gambling industry employees are exposed on a daily basis to gambling, alcohol use and smoking. Out of a concern for the health and well-being of gambling employees, both land-based and online, the International Center for Responsible Gaming (ICRG) invites investigators to propose research projects that will study the possible gambling-related harms and other potential risks to health, of working in the gambling industry. | November 15, 2024. | |
| International | American Foundation for Suicide Prevention (AFSP): Various Opportunities | $50,000 - $150,000 (see opportunities for more information) | AFSP suicide research grants program prioritizes projects in Ethnic and Racial Diversity, Understudied populations with elevated suicide rates, and Survivors of Suicide Loss. Investigators from all academic disciplines are eligible to apply, and both basic science and applied research projects will be considered. | LOI (Required ONLY for Linked Standard Research Grant): September 15, 2024; Full Application: November 15, 2024. | |
| International | Society of Abdominal Radiology (SAR): Bracco Research and Innovation Award | USD $25,000 for 2 years. | This is to facilitate visionary research in medical imaging by making funds available for pilot projects on ideas that are intellectually challenging but not yet well enough developed to be suitable for funding by mainstream granting agencies. At the time of application, the grant applicant must be a SAR member in-good-standing. | November 15, 2024. | |
| International | Society of Abdominal Radiology (SAR): SAR Research Award | USD $25,000 for 2 years. | This is for promising projects in the field of gastrointestinal radiology or genitourinary radiology. At the time of application, the grant applicant must be a SAR member in-good-standing. | November 15, 2024. | |
| International | Cancer Research Institute: Technology Impact Award | Up to USD $200,000 for up to 2 years. | This provides seed funding to address the gap between technology development and clinical application of cancer immunotherapies. These grants aim to encourage collaboration between technology developers and clinical cancer immunologists and to generate the proof-of-principle of a novel platform technology in bioinformatics, ex vivo or in silico modeling systems, immunological or tumor profiling instrumentation, methods, reagents and assays, or other relevant technologies | November 15, 2024. | |
| International | Association for the Advancement of Blood & Biotherapies (AABB) Foundation: Early-Career Scientific Research Grants Program | Up to USD $100,000 for 1 year or 2 years. | These grants are for early-stage investigator-initiated original research in all aspects of blood banking, transfusion medicine and biotherapies. An early-stage investigator is a new investigator who has completed a terminal research degree or medical residency – whichever date is later – within 10 years of the grant application deadline and has not yet been awarded a substantial research grant. | December 1, 2024. | |
| International | Association for the Advancement of Blood & Biotherapies (AABB) Foundation: Process Development Grant | Up to USD $100,000 for 1 year. | This supports improvements to business operations through the development, implementation, and outcomes analysis of innovative processes, techniques or technologies. Proposals that offer potential for widespread dissemination and adoption for the field will receive priority. | December 1, 2024. | |
| International | American College of Gastroenterology (ACG) - Clinical Research Awards: | USD $50,000 for one year. | This will support innovative patient-oriented research with direct applicability to clinical care. | December 2, 2024. | |
| International | American College of Gastroenterology (ACG) - Clinical Research Award Pilot Projects: | USD $15,000 for one year. | This will support innovative patient-oriented research and encourage clinical research among trainees and junior faculty. | December 2, 2024. | |
| International | Cystic Fibrosis Foundation (CCF): Pilot and Feasibility Award | Up to USD $50,000/year up to 2 years. | This supports projects that will develop and test new hypotheses and/or new methods that could eventually contribute to the development of a cure for CF and to support promising new investigators as they establish themselves in research areas relevant to cystic fibrosis. | December 5, 2024 (Fall cycle). | |
| International | Cystic Fibrosis Foundation (CCF): Research Grant | Up to USD $150,000/year for up to 3 years. | This is intended to facilitate or enable the development of new information that may contribute to the development of new therapies for CF, especially projects focused on advancing CFTR repair and replacement strategies. Proposals must be hypothesis driven and contain sufficient preliminary data to justify support from the Cystic Fibrosis Foundation. | December 5, 2024 (Fall cycle). | |
| International | Cystic Fibrosis Foundation (CCF): Postdoctoral Research Fellowships | Up to USD $75,000/year for up to 2 years. | This is intended to enable research training in new research areas and methods to advance the scientific knowledge of the applicant and to collect data to enable their transition into an independent research career. | December 5, 2024 (Fall cycle). | |
| International | ResMed Foundation: Physician and Public Awareness | USD $10,000. | These grants are to further the awareness and knowledge of the inherent dangers of untreated sleep disordered breathing, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public. | December 15, 2024. | |
| International | Society of General Internal Medicine (SGIM): Mary O’Flaherty Horn Scholars in General Internal Medicine Program Grant: | $30,000/year for 2 years, supplemented by matching funds or support of $30,000/year from the scholar’s institution. | This two-year career development award is for junior clinician-educator to support their academic careers while balancing personal and professional responsibilities. Applicants must desire to work part-time, in a 0.5-0.8 FTE position, and agree to allocate the remaining 0.2-0.5 time for dependent care (children, parents, etc.) and self-care and wellness activities. They should be motivated to develop a scholarly project related to provider engagement and wellness, be engaged in caring for underserved patients, and have two committed mentors to support their scholarly activities and a balanced lifestyle. | Nomination Deadline: January 21, 2025. | |
| International | Focused Ultrasound Foundation (FUSF): Research Awards | USD $100,000 for 1 year. | This funds projects involving the use of non-invasive image-guided focused ultrasound to treat disease, including preclinical translational research studies and clinical trials. Funding is prioritized for research in the fields of oncology and neurodegenerative disease. | Continuous. | |
| International | AbbVie Inc.: Investigator-Initiated Study (IIS) Program | -- | This opportunity will support investigator-initiated research that promotes the advancement of medical and scientific knowledge involving AbbVie’s products and therapeutic areas of interest. The research has the capability to expand understanding of AbbVie’s products and their potential applications. Plus, data from IIS research can inform patient care and spark new ideas for further disease-related research. | Continuous. | |
| International | Gateway for Cancer Research: Various Opportunities | Typically in the $200,000 to $1.5 million range for 2-5 years | Gateway funds Phase I and II patient-centered cancer clinical trials that have the potential to shift the paradigm for standard of care. Gateway funds treatment-based studies at the bedside, including all types of cancers. Research areas include Biomarkers (prognostic or predictive with supportive treatment), Gene Therapy, Basket Trials, Immunotherapy, and Targeted Therapies. | Rolling deadlines 3x per year. Anticipated deadlines for 2024: July or August, and November or December. | |
| International | Pre-Announcement: United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP) FY24 Defense Medical Research and Development Program (DMRDP): Psychedelic Treatment Research Clinical Trial Award | USD $4.9M total costs for 3 years. | Applications submitted to the FY24 DMRDP must propose clinical trials with eligible U.S. Service Members to evaluate treatments for posttraumatic stress disorder (PTSD) and/or traumatic brain injury (TBI) involving the use of covered psychedelic substances. Covered psychedelic substances include: 3,4-Methylenedioxy-methamphetamine (commonly known as MDMA); psilocybin; ibogaine; 5-Methoxy-N,N-dimethyltryptamine (commonly known as 5-MeO-DMT); plant-based alternative therapies. | Deadlines will be available when the announcements are released. | |
| International | US Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRPP) Pre-Anouncement: FY24 Trauamtic Brain Injury and Psycholgical Health Research Program (TBIPHRP) - Emerging Research Award | Research Level 1: Up to USD $700,000 for up to 3 years; Research Level 2: Up to USD $1.5M for up to 4 years. | Advances research in emerging topics in in traumatic brain injury and/or psychological health, with a unique set of topic areas aligned with TBIPHRP goals (see website for details). | Deadlines will be available when the announcements are released. | |
| International | US Department of Defense (DOD)Pre-Announcement: Congressionally Directed Research Programs (CDMRP): FY24 Peer Reviewed Cancer Research Program (PRCRP) - Multiple Opportunities | USD $400,000 - $20,000,000 (check opportunities for amounts) | The FY24 PRCRP will provide funds for research into cancers not addressed in the other CDMRP cancer programs. To be considered for funding, applications for the FY24 PRCRP must address at least one of the FY24 PRCRP Topic Areas. The FY24 PRCRP requires all applications to answer at least one of the Military Health Focus Areas listed on the opportunity website. | Deadlines will be available when the announcments are released | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Kidney Cancer Research Program (KCRP): Academy of Kidney cancer Scholars Leadership Award | Up to USD $1,500,000 for up to 5 years. | Supports established kidney cancer researchers with a record of mentoring junior faculty level kidney cancer scientists and/or clinicians. | Deadlines will be available when the announcements are released | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Kidney Cancer Research Program (KCRP): Academy of Kidney Cancer Scholars Early-Career Scholar Award | Up to USD $725,000 for up to 4 years. | Applicant must be within 4 years of last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent, as of full application submission deadline. Preliminary data required. | Deadlines will be available when the announcements are released | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Kidney Cancer Research Program (KCRP): Clinical Trial Award | Up to USD $1,500,000 for up to 4 years. | Supports hypothesis-based, early-phase clinical trials (e.g., Phase 0, Phase 1, pilot Phase 2) to test interventions that will have a major impact in the field of kidney cancer. | Deadlines will be available when the announcements are released | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Kidney Cancer Research Program (KCRP): Concept Award | Up to USD $100,000 for up to 1 year. | Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer. Funding for clinical trials is not allowed. Preliminary data are not allowed and should not be discussed. Blinded review. | Deadlines will be available when the announcements are released | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Kidney Cancer Research Program (KCRP): Idea Development Award | Up to USD $800,000 for up to 4 years; Partnering PI Option: Up to USD $1,200,000 for up to 4 years. | Supports the development of innovative, high-impact ideas that advance the understanding of kidney cancer and ultimately lead to improved outcomes. Preliminary data are required. | Deadlines will be available when the announcements are released | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Kidney Cancer Research Program (KCRP): Translational Research Partnership Award | Up to USD $800,000 for up to 3 years. | Supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in kidney cancer toward clinical applications. | Deadlines will be available when the announcements are released | |
| International | Pre-announcement: United States Department of Defense (DoD): Alcohol and Substance Use Disorders Research Program (ASUDRP) | Estimated maximum funding of $3,525,000 for total costs (direct plus indirect costs) | This is to support research of exceptional scientific merit in the area of alcohol, opioid and other substance use disorders research, including opioid use disorder, particularly when co-occurring with PTSD, TBI and/or other mental health conditions. With the goals to treat alcohol and other substance use disorders, and to improve treatment adherence, prevent relapse and reduce risk of misuse, the applications submitted to the FY24 ASUDRP must address the following focus areas: New medication targets; Novel medications; Re-purposed medications; Vaccines and other immunotherapies; Drug-drug combinations; and More potent, longer-acting formulations to counteract opioid (including fentanyl and its analogs) overdose | Deadlines will be available when the announcements are released | |
| International | Pre-announcement: United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP): Glioblastoma Research Program Anticipated Funding Opportunities for Fiscal Year 2024 (FY24) - Hypothesis Development Award: | Up to USD $300,000 for up to 2 years. | Supports initial exploration of innovative and potentially groundbreaking concepts in glioblastoma research that may lead to promising new products, devices, clinical guidance, or emerging technologies for patient care. | Deadlines will be available when the announcements are released | |
| International | Pre-announcement: United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP): Glioblastoma Research Program Anticipated Funding Opportunities for Fiscal Year 2024 (FY24) - Resource Development Award: | Up to USD $500,000 for up to 3 years. | Supports product-driven research aimed at developing tools for use by the research and/or clinical communities. | Deadlines will be available when the announcements are released | |
| International | King Salman Center for Disability Research (KSCDR): Research Grants | Small projects: SAR $100,000; Medium projects: SAR $500,000; Large projects: Unrestricted. | These support projects into the diagnosis and classification of disability, early-intervention, inclusion of the disabled in education, healthcare, training and employment, and the social, economic and psychological effects of disability. | Rolling. | |
| International | Jeffrey Modell Foundation: Specifc Defect Research Program | up to USD $50,000 for 2 years | Supports research that studies the mechanisms and presentation of specific defects of the immune system to gain a better understanding of the defects and their impact on overall health outcomes. | Applications are accepted and reviewed on a rolling basis, so you may apply at any time. | |
| International | Jeffrey Modell Foundation: C.H.I.L.D.R.E.N!® | up to USD $25,000 for 2 years | Supports research focused on children living with PI throughout the world, while addressing healthcare disparities, especially in developing countries, through education, testing, diagnosis, and treatment. | Applications are accepted and reviewed on a rolling basis, so you may apply at any time. | |
| International | American Psychoanalytic Association (APsaA) Fund for Psychoanalytic Research: Research Grant | USD $20,000 for 1 year. | The funds are dedicated to the support of psychoanalytic research and scholarship, while nuturing the development of psychoanalytic investigators. | May 1 and December 31 of each year. | |
| International | Biogen: Various Opportunities | -- | Biogen considers requests in Biosimilars (Dermatology, Gastroenterology, Ophthalmology, Rheumatology), Multiple Sclerosis, and Spinal Muscular Atrophy in Medical Education, Patient Educaiton and General Grant. | August 15, November 1. | |
| International | AlloSource: Investigator Initiated Research (IIR) Grant Program | Grant requests may include project funding and/or implantable tissue. | AlloSource is working closely with physicians and scientists across multiple orthopedic therapies to continuously improve and bring new allografts to the market, while simultaneously maximizing the gift of donation. | Rolling Deadline | |
| International | Solving Kids' Cancer Therapeutic Development Initiative (TDI) | $50,000 to $500,000 USD for up to 2 years. | Solving Kids' Cancer is a nonprofit organization with a track-record of funding novel clinical research for children diagnosed with high-risk solid tumors specifically neuroblastoma, brain tumors and sarcomas. The TDI's goal is to support innovative early phase clinical studies that are high on the risk/reward spectrum. | Preliminary Proposal Deadline: Rolling | |
| International | Össur Orthopaedic Research Grant Program | -- | This provides funding for scientific inquiry in the areas of lower extremity biomechanics, dynamic/active rehabilitation, ortho biologics, functional bracing, clinical patient outcomes, and, related healthcare economics. | Rolling Deadline | |
| International | Aesculap Implant Systems Investigator-Initiated Study Program (IIS) | Dependent on the type of research and availability of support. | This supports researchers interested in conducting studies of their own design, which promotes the advancement of medical and scientific knowledge related to Aesculap's products and therapeutic areas of focus: Neurosurgery; Surgical Technologies; Closure Technologies; Orthopaedics; Spine; Biologics. | Continuous | |
| International | Bausch + Lomb Grants | -- | Educational Grants: These contribute to the improvement of patient care and advances in the use of healthcare products. Independent Research Grant: These empower the global research community to develop new treatments and technological advancements in ocular health. | Rolling Deadlines. Allow 6-12 weeks for proposal review and decision. | |
| International | Horizon Europe Pillar II: Global Challenges and European Industrial Competitiveness | Within each cluster are a number of calls, which have unique criteria, budgets, and deadlines. | Canadian researchers can now apply for and receive funding directly from this program. Pillar II funding is organised into 6 clusters (i.e., themes), including Cluster 1: Health. A consortium of at least three partners is needed to apply: at least one must be from an EU country and two must be from different EU or associated countries (e.g., Canada). | Within each cluster are a number of calls, which have unique criteria, budgets, and deadlines. | |
| NIH | NIH Parent Announcements | -- | This supports support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitionary phases, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years), and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitionary phases. | https://grants.nih.gov/grants/how-to-apply-application-guide/due-dates-and-submission-policies/due-dates.htm | |
| NIH | NIH Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning | -- | This encourages grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. National Institute on Drug Abuse (NIDA) is interested in applications that make use of existing data. | This notice applies to subsequent receipt dates through September 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19 | -- | National Institute on Drug Abuse (NIDA) is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19. | This notice applies to due dates through September 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection | -- | The purpose of this notice is to communicate NIDA's interest in supporting research on the effects of smoking or vaping toaccor or marijuana on the risk onf acquiring COVID-19 and the clinical course of the infection. | This notice applies to due dates through September 7, 2024. | |
| NIH | NIH Basic Research in Cancer Health Disparities: R01 Clinical Trial Not Allowed | -- | These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities. | This notice applies to due dates through September 8, 2024 | |
| NIH | NIH Basic Research in Cancer Health Disparities: R21 Clinical Trail Not Allowed | -- | This provides support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities. | This notice applies to due dates through September 8, 2024 | |
| NIH | NIH Basic Research in Cancer Health Disparities: R03 Clinical Trail Not Allowed | -- | These small research grants will support projects on cancer health disparities that can be carried out in a short period of time with limited resources. | This notice applies to due dates through September 8, 2024 | |
| NIH | NIH Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to improve use of Evidence-Based Practices for heart, lung, blood, and sleep (HLBS) conditions | -- | This notice is intended to stimulate the use of behaviour economies strategies for implementation research (BEIR) in order to develop more effective strategies for implementation of evidence-based practices (EBP) to address heart, lung, blood, and sleep (HLBS) conditions. | This notice applies to subsequent receipt dates through September 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research | -- | The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the US. Applications examining all areas of National Institute on Drug Abuse (NIDA)-supported research addressing the causes, consequences, treatment, and prevention of drug use, misuse, and addiction are encouraged. | This notice applies to subsequent receipt dates through September 8, 2024. | |
| NIH | NIH BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed) | -- | This seeks the development of theories, computational models, and analytical tools to derive understanding of brain function from complex neuroscience data. It is expected that the the tools developed will be made widely available to the neuroscience research community for their use and modification. | September 12, 2024. | |
| NIH | NIH Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) | -- | This solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfil an unmet need and are capable of enhancing our understanding of life, science processes or the pracice of medicne. | May 24, 2024; September 26, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Health Influences of Gender as a Social and Structural Variable | -- | This notice is to highlight interest in receiving research and training grant applications focused on health impacts of gender-related social and structural variables. For this notice, relevant domains of gender roles and norms, gender relations, gender equity/inequity, gender equity/inequality, gender-related power dynaics, and structural sexism. | September 30, 2024. | |
| NIH | NIH: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | -- | This opportunity is for applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic, clinical, or epidemiological cancer research. | April 1, 2024; October 1, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | -- | This opportunity invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic, clinical, or epidemiological cancer research. | April 1, 2024; October 1, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | -- | This opportunity solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care.The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. | April 1, 2024; October 1, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | -- | This opportunity solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. | April 1, 2024; October 1, 2024. | |
| NIH | NIH HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed) | _ | The focus is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. | February 2, 2024; June 4, 2024; October 2, 2024. | |
| NIH | NIH BRAIN Initative: Targeted BRAIN Circuits Planning Projects - TargetedBCP: R34 Clinical Trials Not Allowed | -- | For applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying hat, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - TargetedBCP R01 | June 28, 2024; October 2, 2024. | |
| NIH | NIH BRAIN Initative: Targeted BRAIN Circuits Planning Projects - TargetedBCP: R01 Clinical Trial Not Allowed | -- | For research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. | June 28, 2024; October 2, 2024. | |
| NIH | NIH: Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | -- | This encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research. | June 5, 2024; October 5, 2024. | |
| NIH | NIH: Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes: Effectiveness Trials (R01 Clinical Trial Required): | -- | NIMH seeks applications for research projects to evaluate the effectivness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This is intended to support trials that are statistically powered to provide a definitive answer regarding the effectiveness of the post-acute phase intervention. | This notice for new applications applies to due dates on or after June 5, 2024 and subsequent receipt dates for new or resubmission applications through October 5, 2024. | |
| NIH | NIH: Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed) | -- | The purpose of this funding opportunity is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities that strengthen the public health impact of NIMH-supported research. | June 5, 2024; October 5, 2024. | |
| NIH | NIH Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment: R01 Clinical Trial Optional | -- | This is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. | October 5, 2024. | |
| NIH | NIH Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment: R01 – Clinical Trial Not Allowed | This is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. | October 5, 2024. | ||
| NIH | NIH Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional) | -- | The National Cancer Institute (NCI) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research. | June 7, 2024; October 8, 2024. | |
| NIH | NIH: Engineering Durable HIV Vaccine Responses (ENDURE) (R01 Clinical Trial Not Allowed) | Up to USD $750,000 direct costs per year for up to 5 years | This notice intends to support basic and applied research integrating immunology and bioengineering to better understand and induce durable HIV vaccine responses. Applicants must propose research with one or more preventative HIV vaccine candidate(s) and must address the durability of immune responses to HIV vaccination. | October 9, 2024 | |
| NIH | NIH Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment | -- | The purpose is to stimulate research that identifies effective strategies for improving interprofessional teamwork and addresses care coordination challenges within care settings and between care settings or during care transitions. Research in this area should advance actionable knowledge about how to design and carry out effective, efficient interprofessional team-based cancer care that improves quality and patient outcomes. | This notice applies to subsequent receipt dates through October 9, 2024. | |
| NIH | NIH Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) | -- | The National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. | February 13, 2024; June 11, 2024; October 11, 2024. | |
| NIH | NIH: Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes: Pilot Effectiveness Trials (R34 Clinical Trial Required) | Up to $450,000 for up to 3 years. | This is support pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials. | This notice for new applications applies to due dates on or after June 16, 2024 and subsequent receipt dates for new or resubmission applications through October 16, 2024. | |
| NIH | NIH: Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required) | -- | This opportunity invites applications to develop and implement multi-site Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure. | October 17, 2024. | |
| NIH | NIH: Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional) | -- | This call is to 1) invite applications that propose to develop and implement early- to late-stage clinical trials of promising pharmacological and non-pharmacological interventions to prevent and/or treat the cognitive, behavioral, and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD), and 2) stimulate studies to enhance trial design and methods. | October 17, 2024. | |
| NIH | NIH: Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional) | Up to $500,000 per year for up to 2 years for the UG3 phase and up to $1,500,000 per year of the UH3 phase for up to 5 years in total for the UG3/UH3 phase. | This is to accelerate the development and early validation of predictive tools and/or biomarkers to inform individual-level treatment selection among two or more existing therapeutics for depression. This phased inter-agency program will be milestone-based and provide support from multi-disciplinary teams to address scientific, technical, clinical, regulatory, and commercialization requirements. | October 18, 2024. | |
| NIH | NIH Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional) | -- | This is to create a pipeline to accelerate the development and early validation of predictive tools and/or biomarkers to inform individual-level treatment selection among two or more existing therapeutics for depression. This phased inter-agency program will be milestone-based and provide support from multi-disciplinary teams to address scientific, technical, clinical, regulatory, and commercialization requirements. | October 18, 2024. | |
| NIH | NIH: Novel Preclinical Models of NeuroHIV in the cART Era (R61/R33 - Clinical Trial Not Allowed) | Up to USD $600,000 in direct costs/year for up to 4 years, with no more than two years for the R61 phase and no more than three years for the R33 phase. | This is to support projects that propose the development and early stage validation of novel small animal models and/or human cellular microphysiological systems of HIV infection that better recapitulate the complex interactions that occur between cells of the CNS and the immune system in people with HIV (PWH). The goal of this initiative is to promote a significant improvement in the translational relevance of NeuroHIV models, specifically in the context of chronic HIV infection of the CNS in the modern antiretroviral therapy (ART) era under conditions of viral suppression. | LOI: November 1, 2024; Application: December 2, 2024 | |
| NIH | NIH: Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD: R01 Clinical Trial Not Allowed: | Up to USD $500,000/year for up to 5 years. | This supports applications focused on uncovering novel mechanisms underlying RNA modification-mediated processes and their impact on brain aging and the pathogenesis and progression of AD/ADRD. | LOI: October 10, 2024; Full Application: November 01, 2024. | |
| NIH | NIH: Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD: R21 Clinical Trial Not Allowed: | Up to USD $275,000 for up to 2 years | This supports exploratory and developmental grant applications focused on uncovering novel mechanisms underlying RNA modification-mediated processes and their impact on brain aging and the pathogenesis of AD/ADRD. Proposed studies should focus on functional characterization and mechanistic investigation of previously identified RNA modifications. | LOI: October 10, 2024; Full Application: November 01, 2024. | |
| NIH | NIH Clinical Trial Readiness for Functional Neurological Disorders (FNDs) (U01 Clinical Trial Optional) | -- | This invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this funding opportunity announcement include the validation of biomarkers, endpoints and clinical outcome assessments that are fit-for-purpose and have a defined context of use for clinical trials | This notice applies to subsequent recipt dates through November 6, 2024. | |
| NIH | NIH: Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA) (U01 Clinical Trial Not Allowed) | NIDA intends to commit $4M in FY 2025 to fund up to seven awards, for up to 5 years | This notice is to seek applications proposing team-science research projects aimed at longitudinal research designs in animal models and advanced neuroscience and theoretical tools to elucidate mechanisms mediating the impact of the early-life social environment on neurobehavioral development and the risk for substance use disorders (SUD) and their comorbidities in adolescence and adulthood. | November 7, 2024 | |
| NIH | NIH: Investigating Mitochondrial-Nuclear Communication in AD/ADRD (R01 Clinical Trial Not Allowed) | -- | This opportunity invites applications that investigate mitochondrial-nuclear communication in the context of neurobiology and Alzheimer's disease (AD) and AD-related dementias (AD/ADRD). This research will transform our understanding of how mitochondrially derived metabolites can impact nuclear gene expression and how changes to nuclear function can impact mitochondrial activity. This has the potential to serve as the foundation for the development of future AD/ADRD therapies that specifically target mitochondrial function as well as shed light on the role that mitochondria play in aging and neurodegeneration. | Letter of intent: October 7, 2024. Application: November 7, 2024. | |
| NIH | NIH: Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) | -- | This is to invite applications proposing research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD). Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this FOA. | This notice for new applications applies to due dates on or after March 11, 2024 and subsequent receipt dates for new or resubmission applications through November 12, 2024. | |
| NIH | NIH: Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trail Optional) | -- | This is to invite applications proposing new tests, animal models, techniques, etc. to advance on Alzheimer's disease (AD) and its related ementias (ADRD) that need additionl preliminary data with broader dissemination to establish them for more general use in this research field. | This notice for new applications applies to due dates on or after March 11, 2024 and subsequent receipt dates for new or resubmission applications through November 12, 2024. | |
| NIH | NIH: Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed) | Up to $275,000 for 2 years. No more than $200,000 may be requested in any single year. | This notice is to support research towards identifying and characterizing neuroimmune networks, communication pathways, and targets that reside within neuroimmune axes, in the context of HIV and substance use. Exploratory projects are appropriate for this notice. | November 13, 2024. | |
| NIH | NIH: Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R01 Clinical Trial Not Allowed) | -- | This notice is to support research towards identifying and characterizing neuroimmune networks, communication pathways, and targets that reside within neuroimmune axes, in the context of HIV and substance use. Applications testing a fully conceptualized premise founded with adequate preliminary data are appropriate for this notice. | November 13, 2024. | |
| NIH | NIH Translational Resource Centers to Build Bridges Between Substance Use Epidemiology/Etiology and Prevention Intervention Research (U24 Clinical Trials Not Allowed) | -- | This notice seek innovative applications for Translational Resource Centers that will establish and support multidisciplinary research teams to conduct translational research between the fields of 1) substance use epidemiology and etiology and 2) substance use prevention intervention. Resource centers are expected to conduct activities that bring investigators in these fields together for active collaboration to develop research questions, design study approaches (with either collection of new data or analysis of existing data), and to develop strategies for application of findings from one field into research in the other field. | November 13, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Interventions to Reduce Chronic Inflammation and Inflammation-Related Morbidity in People Living with HIV/AIDS | -- | This notice encourages applications for clinical and basic and mechanistic research to develop, refine, and/or test interventions that reduce or prevent chronic HIV-associated inflammation, and evaluate whether this ultimately reduces the sequelae of that inflammation. This notice does not support applications proposing an intervention to address acute inflammation, such as that occurring after an injury and/or non-HIV infection. | This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through November 14, 2024. | |
| NIH | NIH Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional) | -- | The purpose is to invite applications proposing innovative analysis of exisiting social science, behavioural, administrative, and neuroimaging data to study the etiology and epidermiology of substance using behaviours (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. | March 4, 2024; August 5, 2024; November 15, 2024. | |
| NIH | NIH Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Opional) | -- | The purpose is to invite applications proposing innovative analysis of exisiting social science, behavioural, administrative, and neuroimaging data to study the etiology and epidermiology of substance using behaviours (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. | March 4, 2024; August 5, 2024; November 15, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | -- | The opportunity invites Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. | June 11, 2024; November 15, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) | -- | This invites Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. | June 11, 2024; November 15, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | -- | This invites Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. | June 11, 2024; November 15, 2024. | |
| NIH | NIH: Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) | -- | This invites exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. | June 11, 2024; November 15, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional) | -- | The purpose is to solicit application for research targeted at eludicating the effect of HIV and/or anit-retroviral therapy on the growth, development and functioning of the placenta in pregnant individuals with substance use/misuse, the impact of placental abnormalities on maternal outcomes, and the underlying mechanisms. | November 16, 2024. | |
| NIH | NIH: Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional) | -- | This opportunity seeks to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental biological mechanisms underlying HIV-associated comorbidities, co-infections, and complications relevant to the mission of NIDDK and advance progress toward preventing or alleviating them. | Letter of intent: October 21, 2024. Application: November 21, 2024. | |
| NIH | NIH: Halting Tuberculosis (TB) Transmission (R01 Clinical Trial Optional) | Up to $750,000 in direct costs per year for up to 5 years | This is to support applications to understand the critical drivers of tuberculosis (TB) transmission at the individual and population levels in high-burden settings; to develop effective methods to measure rates of TB transmission that rely on an increased understanding of the biomedical basis of transmission and related risk factors; and assess potential interventions, including low-cost and low-tech options, to prevent TB transmission and detect infectious TB. | December 04, 2024. | |
| NIH | NIH: Strategies for Eliminating HIV Proteins: R01 | -- | The purpose of this funding opportunity is to support the development of molecules that target HIV proteins or RNA for degradation or that interfere with the translation of HIV RNA into protein. This approach has the potential of eliminating HIV proteins that have been difficult to target via traditional drug discovery methodologies. This stream will support applications which are hypothesis driven and supported by preliminary data. | December 04, 2024. | |
| NIH | NIH: Strategies for Eliminating HIV Proteins: R21: | Up to USD $275,000 for up to 2 years. | The purpose of this funding opportunity is to support the development of molecules that target HIV proteins or RNA for degradation or that interfere with the translation of HIV RNA into protein. This approach has the potential of eliminating HIV proteins that have been difficult to target via traditional drug discovery methodologies. | December 04, 2024. | |
| NIH | NIH Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed) | -- | This supports hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI). | December 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Technology Development for Cancer Control and Population Science Research | -- | This is to encourage grant applications for the development of novel technologies to support the needs of cancer control and population sciences research including healthcare delivery research, surveillance research, behavioral research, cancer epidemiology, and population scale -omics research with the goal of driving innovation in this field. | This notice applies to due dates on or after March 1, 2023 and subsequent receipt dates through December 31, 2024. | |
| NIH | NIH R21: Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed) | -- | The purpose of this is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases. | This notice applies to due dates on or after January 7, 2024 and subsequent receipt dates through January 7, 2025. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional) | -- | This opportunity seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that aligns with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). | This notice applies to due dates on or after May 7, 2024, and subsequent receipt dates through January 7, 2025. | |
| NIH | NIH: Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional) | -- | This opportunity encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. | This notice applies to due dates on or after May 7, 2024 and subsequent receipt dates through January 7, 2025. | |
| NIH | NIH Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed) | -- | This encourages applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently FDA-approved or cleared. For applicants who seek to propose a larger project. Applicants who seek to establish proof-of-concept should respond to the companion R21. | This notice applies to subsequent recipt dates through January 8, 2025. | |
| NIH | NIH Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed) | -- | This encourages applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently FDA-approved or cleared. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope. | This notice applies to subsequent recipt dates through January 8, 2025. | |
| NIH | NIH - Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest | -- | This aims to study the effect of emerging and evolving public health crises and/or policy changes on the health, development, and well-being of populations of interest to the NICHD: neonates, infants, children, adolescents, and young adults, pregnant and post-partum and nursing people, individuals of reproductive age, and individuals with intellectual, developmental, or physical disabilities, as well as the families of these individuals. | This notice applies to subsequent receipt dates through January 8, 2025. | |
| NIH | NIH Drug Discovery for Nervous System Disorders (R01 Clinical Trials Not Allowed) | -- | To stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Applicants with preliminary data may wish to apply using the R01 mechanism. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism. | Standard dates apply until January 8, 2025. | |
| NIH | NIH Drug Discovery for Nervous System Disorders (R21 Clinical Trials Not Allowed) | -- | To stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). This will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics. | Standard dates apply until January 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research | -- | National Institute of Mental Health (NIMH) is issuing this NOSI to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic both specifically related to the virus but also at a broader population level that is impacted by stress, disruptions, and loss of lives in the pandemic. | This Notice applies to subsequent receipt dates through January 8, 2025. | |
| NIH | NIH: Notice of Special Interest (NOSI): Maximizing the Scientific Value of Secondary Analyses of Existing Cohorts and Datasets in Order to Address Research Gaps and Foster Additional Opportunities in Aging Research | -- | This is to encourage the use of existing cohorts and datasets for well-focused secondary analyses to investigate novel scientific ideas and/or address clinically related issues on: (1) aging changes influencing health across the lifespan (e.g., Alzheimer’s disease (AD) and Alzheimer's disease-related dementias (ADRD)), (2) diseases and disabilities in older persons, and/or (3) the changes in basic biology of aging that underlie these impacts on health (the hallmarks of aging). | January 08, 2025. | |
| NIH | NIH: Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) | -- | This is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies among underrepresented communities or that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. | This notice for new applications applies to due dates on or after September 07, 2024 and subsequent receipt dates for new or resubmission applications through February 05, 2025. | |
| NIH | NIH NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required) | -- | This is for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS. | This notice applies to due dates on or after February 8, 2024 and subsequent receipt dates through February 10, 2025. | |
| NIH | NIH Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) | -- | This encourages innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through February 16, 2025. | |
| NIH | NIH Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed) | -- | The study must address questions within the mission and research interests of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. | This notice applies to due dates on or after February 20, 2024 and subsequent receipt dates through February 19, 2025. | |
| NIH | NIH Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed) | -- | This invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. | February 20, 2024; August 19, 2024; February 19, 2025. | |
| NIH | NIH Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed) | -- | This seeks to support initiating and building the next generation of population-based cancer epidemiology cohorts to address specific knowledge gaps in cancer etiology and survivorship. Specifically, it will support methodological work necessary to initiate and build cancer epidemiology cohorts that can address critical scientific gaps. | This notice applies to due dates on or after July 29, 2024 and subsequent receipt dates through February 28, 2025. | |
| NIH | NIH Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed) | -- | This will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/ Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation. | March 15, 2024; March 14, 2025. | |
| NIH | NIH Tobacco Regulatory Science (R01 Clinical Trial Optional) | -- | This is to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). | This notice applies to due dates on or after May 6, 2024 and subsequent receipt dates through May 2, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Public Health Research on Cannabis | -- | The National Institute on Drug Abuse (NIDA) is issuing this notice to encourage grant applications on the effects of changing cannabis laws and policies in the US and globally on public health. Applicants are required to measure and report results using a standard THC unit in all applicable human subjects research. | This notice applies to subsequent receipt dates through May 5, 2025. | |
| NIH | NIH Laboratories to Optimize Digital Health (R01 Clinical Trial Required) | -- | This is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations. | Standard dates apply until May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Research to Prevent Drug Use, Misuse and Addiction | -- | This notice to encourage grant applications in research on the prevention of risky drug use behaviors and addiction. While there has been signficant progress identiying and intervening on risk and protective factors for substnce use, population-level impact of substance use prevention interventions has not yet been achieved. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening | -- | This is to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. It encourages the development and use of innovative and rigorous methods and approaches to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan | -- | This encourages applications proposting to test multilevel strategies and interventions to improve the update of evidence-based screening services across the lifespan and in populations including, but not limited to those experiencing health disparties and those that are underserved. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH National Eye Institute (NEI) Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed) | -- | The goal is to stimulate the use of exisiting human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tool, ethods that hev the potential for significant impact in areas relevant to the NEI mission. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH National Eye Institute (NEI) Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed) | -- | This supports applicants in their planning efforts to conduct collaborative large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. This supports applicants in their planning efforts to conduct collaborative clinical research. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) | -- | This encourages innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. | This notice applies to subsequent receipt dates though May 8, 2025. | |
| NIH | NIH Mutiple-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) | -- | This supports applicatins to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effeciveness, pragmatic and/or implementation research clinical trials. The objective it to present the scientific rationale for the clinical trial and a comprehensive scientific and operation plan that describes it. | This notice applies to due dates on or after February 13, 2024 and subsequent receipt dates through June 11, 2025. | |
| NIH | NIH Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required) | -- | This supports applicatins to develop and implement a Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effeciveness, pragmatic and/or implementation research clinical trials. The objective is to present a comprehensive plan to provide overall project coordination, administration, data management and biostatistical support for the clinical trial proposed. | This notice applies to due dates on or after February 13, 2024 and subsequent receipt dates through June 11, 2025. | |
| NIH | NIH Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) | -- | This supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. | This notice applies to due dates on or after February 13, 2024 and subsequent receipt dates through June 11, 2025. | |
| NIH | NIH NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | -- | This supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This does not support research on basica cancer biology, late-stage clinical trials, risk assessment studies, epidemiological studies or studies of behavioral interventions. | This notice applies to due dates on or after February 13, 2024 and subsequent receipt dates through June 12, 2025. | |
| NIH | NIH Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) | -- | Supports studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through June 16, 2025. | |
| NIH | NIH Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional) | -- | This supports efforts to optimize and evaluate pharmacodynamic (PD) measures the neurophysiological processes that are disrupted within or acoss mental disorders in both healthy humans and in another species relevant to the therapuetic development pipeline. This initative will support inital proof of concent studies aimed at identifying meaures for potential development as preclinical assas for evaluating potential new drug and device therapies and their targets. | This notice applies to due dates on or after February 21, 2024 and subsequent receipt dates through June 20, 2025. | |
| NIH | NIH HEAL Initiative Notice of Special Interest (NOSI): Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery | -- | This is to encourage the development, validation, and replication of animal models that recapitulate the phenotypic and physiologic characteristics of a defined pain type/indication and/or disease-associated pain condition and endpoints or outcome measures that can be used there in. The goal is to improve the translational application of animal models and/or outcome measures for the development of non-addicitve analgesics. | This notice applies to due dates on or after October 18, 2022 and subsequent receipt dates through June 25, 2025. | |
| NIH | NIH: Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) | -- | This initiative intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. | This notice applies to due dates on or after February 27, 2024 and subsequent receipt dates through June 25, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy | -- | This NOSI will support research that focuses on the basic mechanisms of COVID-19 associated thrombosis ranging from vascular endothelial cell injury, the host immune responses, to the coagulation and fibrinolysis systems. Identifying risk factors, or co-morbidities that predispose patients to COVID-19-Associated Coagulopathy (CAC) are also of interest. | This notice applies to due dates on or after June 5, 2023 and subsequent receipt dates through July 5, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Diagnostics and Disease Management Tools for Use in Underserved Populations | -- | This seeks applications for diagnostics and disease management tools that have the power to deliver breakthroughs to enable prevention and treatment of heart, lung, blood and sleep diseases in underserved communities. | This notice applies to due dates on or after February 5, 2022 and subsequent receipt dates through July 6, 2025. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed) | -- | This is to support high-risk, high-impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. | August 2, 2024; August 1, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM) Populations | -- | This encourages research that describes the biological, clinical, behavioral, and social processes that affect the health and development of SGM populations and individuals and their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that will enhance health and development of these populations. | This notice applies to subsequent receipt dates through August 1, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional) | -- | This NOSI supports innovative basic, clinical and translational research that may lead to improved therapies or preventive interventions for HIV in people with Substance Use Disorders (SUD). | This notice applies to due dates on or after July 15, 2023 and subsequent receipt dates through August 15, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01) | -- | This promotes research characterizing the pathobiological processes and mechanisms that drive the onset and progression of lung diseases at a molecular/cellular level, providing a systems-level understanding by studying experimental systems with cellular heterogeneity and 3-D architecture. Projects will utilize ex vivo preparations or 3-D multi-cellular in vitro systems of human lung cells and will employ state-of-art multi-omics measures. | This notice applies to due dates on or after September 25, 2022 and subsequent receipt dates through September 7, 2025. | |
| NIH | NIH: Notice of Special Interest (NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities | -- | This notice is to solicit projects on preventive interventions that address cardiometabolic risk factors across the lifespan in populations that experience health disparities. | This notice applies to due dates on or after October 5, 2022 and subsequent receipt dates through September 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Epidemiology of Drug Abuse | -- | This encourages the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. | This Notice applies to applies to due dates on or after June 5, 2022 and subsequent receipt dates through September 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance Use Prevention and Treatment | -- | This supports research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment, 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams. | This notice applies to subsequent receipt dates through September 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Development and Implementation of Clinical Informatics Tools to Enhance Patients’ Use of Genomic Information | -- | This encourages applications to develop and implement patient-facing genomic-based clinical informatics tools that facilitate or enhance patient-provider electronic communication, patient tracking and registry functions, patient self-management and support, provider electronic prescribing, test tracking, referral tracking, and health care decision-making. | This notice applies to subsequent receipt dates through September 24, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on Addressing Violence to Improve Health Outcomes | -- | This notice is to highlight interest in addressing the role of violence in health outcomes and integrating violence-related screening and interventions into healthcare settings. It is to encourage intervention research focused on addressing exposure to violence to improve individual-level health processes and outcomes. | This notice applies to subsequent receipt dates through October 5, 2025. | |
| NIH | NIH National Library of Medicine (NLM) Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional) | -- | This focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through October 5, 2025. | |
| NIH | NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required) | -- | This invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to the National Institute on Aging (NIA)'s research mission. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2025. | |
| NIH | NIH NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional) | -- | This supports small research projects on cancer that can be carried out in a short period of time with limited resources. | This notice applies to due dates on or after February 22, 2024 and subsequent receipt dates through October 17, 2025. | |
| NIH | NIH HEAL Initative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed) | -- | This supports research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. | |
| NIH | NIH HEAL Initative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed) | -- | This supports research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Computational and Statistical Methods to Enhance Discovery from Health Data | -- | This notice is to highlight its interest in recieving grant applications focused on research that aims to reduce or mitigate gaps and errors in health data sets. This invites research grant applications that propose innovative state-of-the-art methods and generalizable approaches to address problems with large health data sets or analytic tools. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Research Opportunities Centering the Health of Women Across the HIV Research Continuum | -- | The NIH Office of Research on Women’s Health (ORWH) and Office of AIDS Research (OAR), in partnership with our Institute, Center, and Office (ICO) partners are issuing this Notice to highlight interest in receiving HIV research and training grant applications that explicitly and intersectionally center the health needs of cisgender women and girls, and gender-diverse people. Despite tremendous scientific advances that have translated to substantial progress in confronting the HIV epidemic, women – and particularly women of color, young women and girls, and transgender women – and gender-diverse individuals remain disproportionately affected by HIV. | This notice applies to due dates on or after June 20, 2024 and subsequent receipt dates through January 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Impact of Policy Interventions Aimed at Addressing Social Determinants of Health to Improve Functioning and Well-being for People with Serious Mental Illnesses | -- | This will fund research on the impact of social and economic policy interventions that address social determinants of health (SDOH) on improvements in access and engagement with mental health treatment, mental health functioning, and quality of life for people with serious mental illnesses, with special attention to understanding the underlying mediators/change mechanisms of those policies on outcomes. | This notice applies to due dates on or after June 5, 2024, and subsequent receipt dates through January 9, 2026. | |
| NIH | NIH Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional) | -- | The National Institute of Mental Health (NIMH) invites applications that propose to advance innovative research to optimize HIV prevention, treatment, and care. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention. | This notice applies to due dates on or after May 9, 2024 and subsequent receipt dates through January 9, 2026. | |
| NIH | NIH Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional) | -- | The National Institute of Mental Health (NIMH) invites applications that propose to advance innovative research to optimize HIV prevention, treatment, and care. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention. | This notice applies to due dates on or after May 9, 2024 and subsequent receipt dates through January 9, 2026. | |
| NIH | NIH Innovations to Optimize HIV Prevention and care Continuum Outcomes (R34 Clinical Trials Optional) | -- | The National Institute of Mental Health (NIMH) invites applications that propose to advance innovative research to optimize HIV prevention, treatment, and care. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention. | This notice applies to due dates on or after May 9, 2024 and subsequent receipt dates through January 9, 2026. | |
| NIH | NIH Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) | -- | Invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of the participating IC. | This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through January 13, 2026. | |
| NIH | NIH BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) | -- | Seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation of neural cells and circuits, to address major challenges and enable transformative understanding of dynamic signaling in the central nervous system. | This Notice applies to due dates on or after January 19, 2024 and subsequent receipt dates through January 20, 2026. | |
| NIH | NIH BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) | -- | This seeks applications to optimize instrumentation and device technologies for recording and modulation of neural cells and circuits, to address major challenges and to enable transformative understanding of dynamic signaling in the central nervous system. | This Notice applies to due dates on or after January 19, 2024 and subsequent receipt dates through January 20, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03) | -- | National Institute on Drug Abuse (NIDA) seeks research on rigorous hypothesis-driven and theory-based study designs and data analytic methods that will support a new generation of patient centered addiction health services research. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through February 5, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior | -- | The notice encourages collaborations between computtionally and experimentally focused investigators. It seeks the development of machine learning algorithms that are able to mechanistically explain how experimental manipulations after cognitive, affective, or social processing in humans or animals | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through February 5, 2026. | |
| NIH | NIH Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Optional) | -- | This invites applications to accelerate the establishment of effective and reliable biomarkers of Alzheimer’s disease (AD) and AD-related dementias (ADRD) for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. This notice will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signatur. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through February 5, 2026. | |
| NIH | NIH: SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required) | -- | This opportunity encourages applications for multi-center clinical trials focused on neurological emergencies (excluding stroke). The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. | This notice applies to due dates on or after June 10, 2024 and subsequent receipt dates through February 6, 2026. | |
| NIH | NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required) | -- | This encourages applications for multi-center clinical trials focused on neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN. | This notice applies to due dates on or after February 6, 2024 and subsequent receipt dates through February 6, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): School Mental Health: Innovative Approaches to Expand Access to Evidence-Based Interventions and Services | -- | This notice is to outline priorities for school-based intervention and services research and encourages applications that incorporate: (1) end-user/community-engaged approaches with systematic attention to challenges related to gaining access to schools, competing demands/workload issues, workforce shortages, and privacy concerns; (2) research-practice partnerships that leverage existing practice infrastructure (3) plans to quantify the resources necessary to implement the intervention, tool, or strategy; and (4) strategies that promote health equity. | This notice applies to due dates on or after June 5, 2024, and subsequent receipt dates through March 17, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) | -- | This notice will support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. | This notice applies to due dates on or after January 7, 2024 and subsequent receipt dates through May 7, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services | -- | This notice is to outline priorities for research in crisis response services. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related, geographic, cultural considerations, and health disparities influence the types of care that are provided. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through May 8, 2025. | |
| NIH | NIH NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed) | -- | This encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the National Institute of Allergy and Infectious Diseases (NIAID). | This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through May 13, 2026. | |
| NIH | NIH Secondary Analysis and Integration of Exisiting Data to Eludicate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) | -- | This encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes. The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through June 5, 2026. | |
| NIH | NIH Secondary Analysis and Integration of Exisiting Data to eludicate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) | -- | This encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes. The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through June 16, 2026. | |
| NIH | NIH Social disconnection and Suicide Risk in Late Life (R01 clinical Trial Not Allowed) | -- | This is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through June 5, 2026. | |
| NIH | NIH Social disconnection and Suicide Risk in Late Life (R21 clinical Trials Not Allowed) | -- | This is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through June 16, 2026. | |
| NIH | NIH BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21 Clinical Trial Not Allowed) | -- | This seeks applications for unique and innovative recording and/or modulation technologies that are in the earliest stage of development, including new and untested ideas that are in the initial stages of conceptualization. Some projects may aim to increase recording or modulation capabilities by many orders of magnitude, while others may aim to improve the precision and selectivity of recording or modulation. | This notice applies to due dates on or after June 18, 2024 and subsequent receipt dates through June 15, 2026. | |
| NIH | NIH Mechanistic Research on Neuromodulation for Substance Use Disorders Treatement (R01 Clinical Trial Optional) | -- | Studies proposed should identify and validate new neuromodulation targets and provide a comprehensive understanding of the behavioral and neurobiological effects of stimulation to these targets and their constituent brain networks. | This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through August 14, 2026. | |
| NIH | NIH Mechanistic Research on Neuromodulation for Substance Use Disorders Treatement (R01 Basic Experiemental Studies wth Humans Required) | -- | For studies that meet both the definition of basic research and the NIH definition of a clinical trial. Types of studies that should submit include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. | This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through August 14, 2026. | |
| NIH | NIH Mechanistic Research on Neuromodulation for Substance Use Disoders Treatement (R61/R33 Clinical Trial Optional) | -- | Supports applications that are expected to be exploratory and developmental in nature. As such, these studies may involve considerable risk of failure but may lead to a breakthrough in a particular area that could have a major impact on SUD research involving NIBS. | This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through August 14, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Promoting implementation research to address HIV-associated comorbidities and risk factors within well-established cohorts (R01 Clinical Trial Optional) | -- | This seeks to support dissemination and implementation (D&I) research proposals leveraging well-established cohorts of people living with HIV (PLWH) to increase the acceptability, feasibility, implementation, scale-up, scale-out, and sustainability of evidence-based interventions (EBIs) that target comorbid conditions and diseases. This NOSI hopes to promote new or existing collaborative efforts between observational, interventional, and D&I scientists, which is a crucial next step to ensure maximal public health impact of clinical trial and cohort studies. | This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through September 7, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Mental Health Comorbidities in HIV Prevention and Treatment | -- | This notice solicits applications focused on understanding and addressing the impact of mental health comorbidities, including mental health disorders, violence, and trauma, on HIV prevention and treatment outcomes. | This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through September 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Intersectional Stigma and Discrimination (ISD), or Other Social and Structural Determinants of Health (SSDOH) in HIV Prevention and Treatment | -- | This notice solicits theoretically- and empirically-driven research applications which will: 1) advance measurements and understanding of HIV-related ISD or intersectional social-structural factors to examine the mechanisms and pathways by which they are barriers to HIV prevention and HIV treatment; 2) develop and test interventions to address their impact to improve HIV prevention and HIV treatment outcomes; or 3) conduct implementation science research of evidence-based interventions. | This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through September 8, 2026. | |
| NIH | NIH R21: Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional) | -- | This notice is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). | This notice applies to due dates on or after October 16, 2023 and subsequent receipt dates through September 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on HIV-associated Malignancies | -- | This notice calls for proposals that seek to identify specific contributions of HIV infection and its potential interaction with other oncogenic pathogens on the development and pathogenesis of malignancies, including studies that provide new information on the clinical outcomes of such cancers in the HIV-infected population. | This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through September 8, 2026. | |
| NIH | NIH Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional) | -- | This notice is to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. It is to seek applications that further the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026. | |
| NIH | NIH Notice of Funding (NOFO) - Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional) | -- | This seeks to support the rigorous assessment of barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. The opportunity is intended to address a critical need for improved care delivery and outcomes for SGM cancer survivors. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026. | |
| NIH | NIH: National Cancer Institute's (NCI) Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | -- | The NCI is soliciting research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the Division of Cancer Treatment and Diagnosis (DCTD), and Office of HIV and AIDS Malignancies (OHAM). | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026. | |
| NIH | NIH: Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | -- | This supports investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026. | |
| NIH | NIH BRAIN Initiative: Brain-Behavior Quantification and Synchronization Transformative and Integrative Models of Behavior at the Organismal Level (U01 Clinical Trial Optional) | -- | This seeks applications that bring together transdisciplinary teams and aim to 1) develop, validate, and apply cutting-edge tools and methods for minimally invasive, multi-dimensional, high-resolution objective measurement of behavior at the organismal level, with synchronous capture of dynamic environmental data; 2) develop advanced analytic approaches to integrate multidimensional behavioral, neural and environmental data; and 3) develop and test new theoretical and computational models aiming to advance understanding of behavior as a complex dynamic system. | October 9, 2024; October 9, 2025; October 9, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Assessing Real-World Effectiveness and Implementation of Telehealth-Guided Provider-to-Provider Communication among Rural Communities | -- | This notice is intended to support the use of the telehealth interventions and tools aimed at the prevention, management and treatment of heart, lung, blood, and sleep conditions, and of cancer in rural communities. The purpose of this notice is to provider-to-provider telehealth (PPT) is defined broadly to include any health technology meant to connect healthcare providers to one another for the care of patients. | This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through October 9, 2026. | |
| NIH | NIH Prevention and Intervention approaches for Fetal Alcohol Spectrum Disorders (FASD) (R61/R33 Clinical Trial Optional) | -- | This is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through October 16, 2026. | |
| NIH | NIH Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disoders (FASD) (R34 Clinical Trial Optional) | -- | This R34 planning grant applications focuses on prevention and intervention strategies for FASD throughout the lifespan. The intent is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through October 16, 2026. | |
| NIH | NIH Ethical, Legal and Social Implications (ELSI): Small Research Grant (R03 Clinical Trial Optional) | -- | This is for research that examines the ELSI of human genetic or genomic research. Applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. | This notice applies to due dates on or after February 19, 2024 and subsequent receipt dates through October 16, 2026. | |
| NIH | NIH Ethical, Legal and Social Implications (ELSI):Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | -- | This is for studies of the ELSI of human genetic or genomic research. Applications may propose studies using either single or mixed methods, that break new ground, extend previous discoveries in new directions, or develop preliminary data in preparation for larger studies. | This notice applies to due dates on or after February 20, 2024 and subsequent receipt dates through October 20 2026. | |
| NIH | NIH Ethical, Legal and Social Implications (ELSI):Research (R01 Clinical Trial Optional) | -- | This is for applications that propose to study the ELSI of human genetic or genomic research. Applications may propose studies using either single or mixed methods. | This notice applies to due dates on or after February 20, 2024 and subsequent receipt dates through October 20 2026. | |
| NIH | NIH: Notice of Special Interest (NOSI): Development of Organotypic Culture Models for Transplantation Immunology Research | -- | This notice encourages applications that focus on the development and validation of tissue-, stem-, or progenitor-cell-derived “3D” organotypic culture models (OCM) for transplantation immunology research. This will support applications that focus on development of allogeneic or xenogeneic OCM to study immunologic features of transplant-related diseases or conditions. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through November 16, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe) | -- | This encourages R21 applications proposing innovative high-risk/high-reward research projects, that test novel hypotheses or develop novel technologies, to advance our understanding of cancer immunology. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through November 17, 2026. | |
| NIH | NIH: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional) | -- | The purpose of this opportunity is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer unprecedented opportunities to develop clinical-grade mobile, web, or other software-based platforms designed to deliver treatments that are safe and effective for SUD. | This notice applies to due dates on or after March 26, 2024, and subsequent receipt dates through November 19, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Leveraging Existing and Accessible Datasets for Implementation Research Strategies and Testing - LEAD FIRST | -- | This notice promotes the use of existing and accessible datasets to inform community-engaged dissemination and implementation (D&I) research on heart, lung, blood and sleep conditions to advance health equity. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through January 7, 2027. | |
| NIH | NIH: Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional) | -- | This notice is to encourage theoretically driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through January 7, 2027. | |
| NIH | NIH: Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional) | -- | This opportunity invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives (1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and (2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. | This notice applies to due dates on or after May 7, 2024 and subsequent receipt dates through January 7, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Supporting Exploratory/Developmental Research Focused on National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Core Mission Areas | -- | This will provide support for innovative projects that introduce novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential for significant impact, and to substantially advance research within the NIAMS mission. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs of high value to the NIAMS research community. | This notice applies to due dates on or after June 16, 2023 and subsequent receipt dates through January 8, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Advancing Data Science Research in HIV: Responding to a Dynamic, Complex, and Evolving HIV Epidemic with Artificial Intelligence/Machine Learning | -- | This seeks to advance data science research in HIV by encouraging the generation of cutting-edge synthetic datasets, artificial intelligence, and machine learning approaches to expand our capacity to address the dynamic, complex, and evolving HIV epidemic. | This notice applies to due dates on or after January 7, 2024 and subsequent receipt dates through January 8, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Behavioral Tasks Targeting Brain Systems Relevant to Anhedonia | -- | This is to encourage research on task-based behavioral measures that engage brain systems relevant to anhedonia. These behavioral measures are expected to be used as a proxy for brain target engagement, therefore neuroimaging or other brain measures with similar spatial resolution should be used to demonstrate that the proposed behavioral tasks engage brain systems relevant to anhedonia. | This notice applies to due dates on or after February 5, 2024, and subsequent receipt dates through January 8, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Advancing Genomic Technology Development for Research and Clinical Application | -- | This notice is to encourage applications focused on developing novel laboratory-focused tools and technologies that enable new lines of scientific inquiry and advance research or clinical applications in human genomics. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through January 10, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI): Advancing Genomic Technology Development for Research and Clinical Application | -- | This is to encourage applications focused on developing novel laboratory-focused tools and technologies that enable new lines of scientific inquiry and advance research or clinical applications in human genomics. Research proposed in response to this NOSI should be generalizable, comprehensive, high-throughput and genome-scale. | This notice applies to due dates on or after September 5, 2024 and subsequent receipt dates through January 10, 2027. | |
| NIH | NIH: NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) | -- | This notice encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. | This notice applies to due dates on or after May 13, 2024 and subsequent receipt dates through January 13, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Fundamental Mechanisms and Functions of Co-transmission in the Brain | -- | This notice encourages basic neuroscience research in animals to investigate the fundamental mechanisms and functions of co-transmission (i.e., release of multiple neurotransmitters by one neuron) that support brain activity and behavior. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through February 4, 2027. | |
| NIH | NIH: New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional) | -- | The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop new approaches or apply existing approaches in novel ways to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease. | This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through February 5, 2027. | |
| NIH | NIH: High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) | -- | This is to support high priority research at the intersection of HIV and substance use. This NOFO invites research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use addictive substances. | This notice for new applications applies to due dates on or after January 11, 2024 and subsequent receipt dates for new or resubmission applications through February 11, 2027. | |
| NIH | NIH: New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional) | -- | The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop exploratory, highly novel new approaches, or innovative applications of existing approaches, to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease, by improving repeated measures across longer epochs of the lifespan to better predict outcomes at later ages. | This notice applies to due dates on or after June 16, 2024 and subsequent receipt dates through February 16, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI): Research to Stimulate Development of Diagnostics, Therapeutics, and Vaccines for Herpes Simplex Virus (HSV) | This notice is to encourage applications which are focused on development of diagnostics, therapeutics, and vaccines for herpes simplex virus (HSV). The NIH Strategic Plan for HSV Research focuses on four strategic priorities: HSV virology basic research, better HSV diagnostics, strategies to address HSV treatment and cure, and research to prevent HSV infection. This NOSI focuses on furthering the development of new products for prevention of HSV infection, as well as improving the diagnosis and treatment of patients living with herpes, addressing three of these four strategic priorities. | This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through April 5, 2027. | ||
| NIH | NIH: Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional) | -- | This opportunity invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approach. | This notice applies to due dates on or after June 16, 2024 and subsequent receipt dates through May 7, 2027. | |
| NIH | NIH: Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional) | -- | This opportunity invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approach. | This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through May 7, 2027 | |
| NIH | NIH Notice of Special Interest (NOSI): Saving Lives: Integrating Overdose Education and Naloxone Distribution (OEND) into HIV Prevention and Care Settings for People Who Use Addictive Substances | -- | This notice calls for research to build a body of evidence on how to implement and sustain OEND in HIV prevention and care settings. Research should develop and test models for integrating OEND; examine barriers and facilitators to successful implementation; and develop implementation strategies to address provider, organizational, structural, reimbursement and other factors impacting implementation. | This notice applies to due dates on or after May 7, 2024 and subsequent receipt dates through May 8, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Neuromodulatory Control of Circuits Underlying Mental Health Relevant Behaviors | -- | This notice solicits applications seeking to understand how neuromodulatory signals dynamically control and coordinate neural circuit responses in real-time during complex mental health relevant behaviors including cognitive, social, and affective functions. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through May 10, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Improving Adherence to Treatment and Prevention Regimens and Maintenance of Health Behaviors to Promote Health | -- | This calls for research grant applications that address adherence to recommended treatment and prevention regimens or maintenance of behaviors to promote positive health outcomes (collectively referred to as health behaviors). Applications may address health behavior initiation, execution, and/or persistence through mechanistic studies, efficacy trials, or implementation research. Descriptive studies and intervention research may address relevant determinants at one or more levels of ecologic influence, including the individual, caregiver/family, provider, healthcare system, and community levels. Approaches designed to reduce health disparities and improve equitable health outcomes are strongly encouraged. | This notice applies to due dates on or after July 15, 2024 and subsequent receipt dates through July 14, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI) Using the Collaborative Cross (CC) Mouse Model for Immunoregulatory and Infectious Disease Research | -- | The purpose of this NOSI is to demonstrate NIAID’s interest in research to continue validating the utility of CC mouse lines to 1) more faithfully reproduce human immune responses and advance our understanding of the host genetics involved in immune regulation/function and 2) to select and evaluate CC and CC-RIX mouse lines suitable for specific studies and disease models within research areas of interest to NIAID. | This notice applies to due dates on or after October 5, 2024 and subsequent receipt dates through July 16, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI): Understanding the Immune Functions of DEAD/H-box Helicases | -- | This is to encourage innovative research on the role of DEAD/H-box helicases in immune homeostasis and activation/function at steady state and in response to immune-mediated or infectious diseases. | This notice applies to due dates on or after October 5, 2024, and subsequent receipt dates through July 16, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Advancing Research to Address the Heterogeneity of Obesity Risk, Related Health Outcomes, and Response to Treatment | -- | This notice is to support research applications that address knowledge and portfolio gaps regarding the role of obesity in disease development. Understanding the heterogeneity of obesity is necessary for precision and targeted implementation of obesity prevention and treatment interventions. | This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through September 7, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI): Supporting Research Using the Resources from the Osteoarthritis Initiative (OAI) | -- | This is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute on Aging (NIA) are interested in receiving research grant applications that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data, and images. | This notice applies to due dates on or after October 5, 2024, and subsequent receipt dates through September 7, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI): Systems Modeling of Infection and Immunity Across Biological Scales | -- | This is to advance computational modeling approaches and technologies focused on infectious, allergic, and/or immune-mediated diseases across different biological scales. Projects will also have the opportunity to collaborate with the NIAID CoE for Systems Modeling of Infection and Immunity across Biological Scales. | This notice applies to due dates on or after October 5, 2024 and subsequent receipt dates through September 7, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Women’s Health Research | -- | This notice is to highlight interest in receiving research applications focused on diseases and health conditions that predominantly affect women (e.g., autoimmune diseases; depressive disorders, Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD), gender-based-violence), present and progress differently in women (e.g., cardiovascular disease; HIV; reproductive aging and its implications), or are female-specific (e.g., uterine fibroids; endometriosis; menopause). | This NOSI applies to due dates on or after May 6, 2024, and subsequent receipt dates through November 4, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI): Developing and Testing Multi-level Physical Activity Interventions to Improve Health and Well-Being | -- | This notice is to increase and maintain health-enhancing physical activity in a wide range of population groups, including populations that experience health disparities, children, older adults, and persons at risk for mental/behavioral health conditions, and any subpopulations that can be characterized by the intersection of two or more of these descriptors. | This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through November 14, 2027. | |
| NIH | NIH NOSI: Research on Illicit Drug Markets | -- | This is to encourage research that examines illicit drug markets and informs prevention, intervention, treatment, and harm reduction efforts. Applications are strongly encouraged to consider who the end-users of the research findings will be (e.g., policy-makers, prevention scientists, local health departments, etc.), and if/when appropriate, include possible end-users in the research team to ensure that the knowledge generated will have real-world impact. | This notice applies to due dates on or after October 5, 2024 and subsequent receipt dates through September 8, 2028. | |
| NIH | NIH Notice of Special Interest (NOSI): Model-informed Drug Development (MIDD) Approaches to Facilitate the Development of Therapeutics for Substance Use Disorders | -- | This NOSI encourages, but is not limited to, research applications that use MIDD approaches to: Predict drug toxicology profile, pharmacokinetics; Assist in pre-formulation studies, formulation design and optimization; Optimize clinical trial design; Support efficacy extrapolation in a new patient population; and Develop precision medicines or personalized treatment plans for special patient sub-populations. | This notice applies to due dates on or after June 5, 2025 and subsequent receipt dates through September 8, 2028. |
